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ABSTRACT
PTSD SYMPTOM SEVERITY AND NEUROCOGNITIVE PERFORMANCE AS
A FUNCTION OF COMBINED TMS AND IMAGINAL EXPOSURE IN OIF/OEF
COMBAT VETERANS WITH TREATMENT RESISTANT PTSD
Katharine Surella Seagly
Virginia Consortium Program in Clinical Psychology, 2015
Director: Dr. Serina A. Neumann

Posttraumatic Stress Disorder (PTSD) is a commonly occurring mental health
diagnosis, and is particularly prevalent in combat veterans. Although there has been
some success treating PTSD with various forms of therapy, many cases remain refractory
to the current standard of care. This pilot study combines transcranial magnetic
stimulation (TMS) to the right dorsolateral prefrontal cortex (DLPFC) and the
supplementary motor area (SMA) with a standardized exposure protocol for the treatment
of chronic, treatment-resistant PTSD. The aims are to (1) determine if the treatment is
safe and well tolerated, (2) determine if PTSD and concomitant depression and anxiety
symptoms improve, and (3) determine if executive functioning and memory improve.
Results indicated the treatment was safe and well tolerated, and improvements were seen
across psychological symptoms. Neurocognitively, improvements were seen in executive
functioning but not in non-executive memory. Statistically significant results must be
interpreted with caution due to the likelihood of sampling error associated with a small
sample size. However, clinical results were striking, with six of the seven participants no
longer meeting criteria for PTSD by the end of the study. Clinical results for this pilot
study were promising and warrant further investigation with larger sample sizes utilizing
a RCT model to confirm and expand upon these preliminary findings.
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CHAPTER 1
INTRODUCTION
Posttraumatic Stress Disorder (PTSD) occurs in as many as one-third to one-half
of those exposed to traumatic events (American Psychiatric Association [APA], 2000),
and is particularly prevalent in combat veterans (United States Department of Veterans
Affairs, 2011). Although there has been some success treating PTSD with various forms
of therapy, up to 58% of cases are refractory to the current standard of care (Foa, Keane,
Friedman & Cohen, 2009; Schnyder, 2005). In addition to the emotional and
psychological dysfunction experienced with PTSD, many patients also undergo a
debilitating decline in neurocognitive functioning (Polak, Witteveen, Reitsma, & Olff,
2012; Uddo, Vasterling, Brailey, & Sutker, 1993).
Initial functional neuroimaging research on PTSD showed increased oxygen
perfusion in the right prefrontal cortex as participants were retold their traumatic events
(Rauch, van der Kolk, Fisler & Alpert, 1996). This finding was replicated in most
subsequent studies (Lanius, Blugm, Lanius, & Pain, 2006; McCann et al., 1998; Post,
Weiss, Smith, Li, & McCann, 1997), resulting in the common understanding that rightsided activity in PTSD is associated with the role of the right hemisphere in anxiety and
other PTSD symptomatology (Ousch et al., 2009; Rauch, van der Kolk, Fisler, & Alpert,
1996; Simmons, Matthews, Stein, & Paulus, 2004). More recent research has also
implicated an over-active supplementary motor area (SMA) in PTSD symptom
maintenance (Shaw et al., 2009; Whalley, Kroes, Marijn, & Huntley, 2013). It follows
then that low-frequency transcranial magnetic stimulation (TMS), a means of decreasing
perfusion and cortical neuronal activity (Hoffman & Cavus, 2002; Huang, Edwards,
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Bhatia, & Rothwell, 2004; Speer et al., 2000) applied to the right prefrontal cortex as well
as the SMA would likely improve functional brain abnormalities associated with PTSD.
Due to established models of PTSD as a malfunction in fear extinction
(Berkowitz, Coplan, Reddy & Gorman, 2007; Martel et al., 2012; Yehuda & LeDoux,
2007), it is likely to be particularly important to bring the neural circuits and the
autonomic arousal involved in the conditioned fear ―on-line‖ when trying to extinguish
the fear response. One method for bringing the conditioned fear on-line is through
imaginal exposure. Imaginal exposure is used to treat PTSD by exposing patients to
memories of their traumatic events in a safe, controlled setting in order to desensitize
them to the trauma and help them to learn that they are no longer in danger (Cahil & Foa,
2005). As such, combining low-frequency TMS and imaginal exposure to treat PTSD
may be more effective than conducting either treatment individually.
The first aim of the present study is to investigate the safety and efficacy of
combined TMS and prolonged imaginal exposure. The goal of this aim is to provide
information regarding the utility of TMS as an additional modality of treatment for
PTSD. The second aim of this study is to examine changes in neurocognitive functioning
from pre- to post-treatment. The rationale for this second aim stems from literature
indicating that PTSD is often accompanied by a decline in cognitive abilities, particularly
in the areas of memory and executive functioning (Polak et al., 2012; Uddo et al., 1993).
PTSD Defined
It is well-documented in the scientific literature that traumatic events can lead to
symptoms of PTSD (American Psychiatric Association, 2013; Brewin, Andrews, &
Valentine, 2000; Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995). The more
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prolonged and more severe a traumatic event, the more likely the person exposed will
exhibit symptoms. According to the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR; APA, 2000)1, PTSD is a group
of symptoms that follow ―exposure to actual or threatened death, serious injury, or sexual
violence.‖ This exposure can include experiencing, witnessing, or learning about the
traumatic event (Criterion A). A diagnosis of PTSD also requires the following:
persistent re-experiencing of the event, such as distressing memories, dreams, or
flashbacks (Criterion B); persistent avoidance of stimuli associated with the traumatic
event, which may include avoidance of memories, thoughts, or feelings about the event,
or avoidance of external reminders such as people or places (Criterion C); persistent
symptoms of increased arousal, such as irritability and angry outbursts, hypervigilance,
problems with concentration, and an exaggerated startle response (Criterion D). These
symptoms must have been present for more than one month (Criterion E) and must cause
significant distress or impairment (Criterion F; APA, 2000).
PTSD Prevalence
Community-based studies indicate that the approximate lifetime prevalence for
PTSD is 8.7% of the adult population in the United States, or about 27 million people
(APA, 2013). Women are more than twice as likely as men to have PTSD at some point
in their lives according to the National Comorbidity Survey Replication (NCS-R; Kessler,
Berglund, Demler, Jin, Merikangas & Walters, 2005), however combat-related PTSD is
much more prevalent in men as the U. S. Department of Defense has only recently

1

The CAPS for the DSM-V was not yet available at the start of the present study. As such, DSM-IV
criteria were used for the diagnosis. Clinically, all participants also met criteria for a DSM-V diagnosis of
PTSD, which overlaps a great deal with the DSM-IV diagnosis, but again, a standardized, objective
measure for these criteria was unavailable.
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permitted women to serve in combat positions (Roulo, 2013). Studies of individuals who
are considered high-risk for PTSD (i.e., those exposed to specific traumatic events) reveal
variable findings with prevalence rates ranging from one-third to more than one-half of
those exposed to rape, military combat and captivity, and ethnically or politically
motivated internment and genocide (APA, 2000). According to the most recent estimate
from the United States Department of Veterans Affairs, approximately 11-20% of
Veterans of the Iraq and Afghanistan wars (Operations Iraqi and Enduring Freedom; OIF
and OEF respectively), have been diagnosed with PTSD (2011). This constitutes a 211% increase over rates in the general population.
Factors other than gender and combat experience increase potential for PTSD
risk. Those with low socioeconomic status (SES) are more likely to develop PTSD
(Chiu, de Roon-Cassini, & Brasel, 2011). However, research also shows that PTSD has
negative consequences for income and employment, thus contributing to a decline in SES
among those with this diagnosis. A lifetime diagnosis of PTSD is associated with a
nearly 50% lower probability of current employment (Savoca & Rosenheck, 2000), and
Veterans with PTSD are three times more likely to be unemployed (Zatzick et al., 1997).
Thus, the effects of PTSD extend to the realm of occupational dysfunction and financial
strain.
Standard of Care for PTSD
The standard treatments available for PTSD typically include medication therapy,
which has limited efficacy as compared to psychotherapy (Van Etten & Taylor, 1998), as
well as exposure-based and cognitive therapies, such as Prolonged Exposure (PE),
Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and
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Reprocessing (EMDR; Benedek, Friedman, Zatzick, & Ursano, 2009; Cloitre, 2009; Foa
et al., 2009). The American Psychological Association [APA] Division 12 lists PE and
CPT as having ―strong research support‖ as evidenced by two or more randomized
controlled trials indicating their effect (APA, 2013). EMDR is considered
―controversial‖ as numerous studies have shown the mechanism of action to be the
exposure component rather than the eye movement (APA, 2013). Briefly, as a
comparison to the PE utilized in the present study, the basic premise of CPT contends
that changing the content of cognitions about a trauma can impact emotional and
behavioral responses to the trauma. Essentially, CPT is a cognitive therapy that focuses
initially on the question of why the trauma occurred and then the effects of the trauma on
the clients’ beliefs about themselves, others, and the world through the use of progressive
worksheets. It is typically administered in 12 90-minute sessions (APA, 2013). PE,
described in detail in the procedures section, involves repeated exposure to traumarelated thoughts, feelings, and situations as this can help reduce the power they have to
cause distress. Essentially, PE consists of imaginal exposures, which involve recounting
the traumatic memory and processing the revisiting experience, as well as in vivo
exposures in which the client repeatedly confronts trauma-related stimuli that were safe
but previously avoided. It is typically administered in 8-15 sessions lasting 60-120
minutes each (APA, 2013). And so, CPT attempts to break into the cycle of PTSD
maintenance at the level of cognition whereas PE attempts to break into the cycle at the
level of experience. EMDR is not considered here due to consistent evidence that it is
just an alternate version of prolonged exposure therapy (APA, 2013).
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While some patients find these treatments to be effective, studies of cognitivebased therapies show drop-out rates around 20%. Furthermore, the current treatment
options have a limited effect on PTSD symptoms. Up to 58% of those who complete
treatment continue to meet criteria for a PTSD diagnosis even after treatment, while only
32–66% obtain a satisfactory level of functioning (Foa et al., 2009; Schnyder, 2005).
Thus, PTSD remains a chronic illness for many individuals, despite treatment. Those
with chronic PTSD also have high rates of psychiatric and medical comorbidities
(Jacobsen, Southwick, & Kosten, 2001; McFarlane, 2010), as well as suicidality
(Panagioti, Gooding & Tarrier, 2012). Due to the prevalence and level of debilitation
effected by this diagnosis, the severity of comorbidities, and given that a large number of
patients do not recover with the current standard of care, it is imperative that we continue
to extend the knowledge base on effective treatment options for PTSD.
Neurobiological Substrates of PTSD
The Dorsolateral Prefrontal Cortex. The dorsolateral prefrontal cortex
(DLPFC) is partially responsible for executive functions such as integration of sensory
and mnemonic information, and the regulation of intellectual function and action,
particularly in relation to impulse control. Damage to the DLPFC can result in the
problems with affect, social judgment, executive memory, abstract thinking, and
intentionality (Zelazo & Muller, 2002), all of which are criteria for, or often accompany,
PTSD (APA, 2013). Additionally, a specific pattern of prefrontal and limbic
abnormalities in PTSD is suggested by neuropsychological tests sensitive to frontal lobe
damage. Specifically, research shows impaired performance on tests reflecting
abnormalities of the dorsolateral prefrontal cortex, the orbitofrontal cortex, and the limbic
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system in general (Bremner et al., 1995; Cohen et al., 2004; Koenen, et al., 2001;
Vasterling, Brailey, Constans, & Sutker, 1998).
Neuroimaging studies have also shown that patients with PTSD have increased
blood flow and glucose utilization in right frontal, limbic, and paralimbic brain structures,
including the right DLPFC, particularly when they are recalling the traumatic event
associated with their symptoms (Lanius et al., 2006; McCann et al., 1998; Post, Weiss,
Smith, Li & McCann, 1997). When considered together, these findings suggest that right
frontal, limbic and paralimbic structures are closely associated with PTSD abnormalities
and could potentially be the target of neurobiological treatment strategies.
The Amygdala. Amygdala responsivity has been shown to be positively
associated with PTSD symptom severity in five independent studies (Armony, Corbo,
Clément, & Brunet, 2005; Pissiota et al., 2002; Protopopescu et al., 2005; Rauch et al.,
1996; Shin et al., 2004). When considering the role of the amygdala in PTSD, it is
helpful to think of associative learning responses. For instance, a soldier might react with
arousal and fear (the unconditioned response [UCR]) to traumatic experiences in combat,
which would serve as the unconditioned stimulus (UCS). As time goes by, the soldier
may continue to exhibit arousal and fear responses in the absence of traumatic events (the
conditioned response [CR]). The response may be elevated when he encounters specific
environmental cues that he associates with the previous trauma (the conditioned stimulus
[CS]). This model applying associative learning to PTSD converges with both animal
and human studies that point to the amygdala as one of the principal structures necessary
for fear learning.
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Studies involving lesioning, electrical stimulation, and site-specific pharmacology
methods show the amygdala receives information about both unconditioned and
conditioned stimuli and is responsible for integrating this information and then activating
fear responses (Kaplan & Moore, 2011; Kim & Jung, 2006). Sensory pathways usually
extend to the amygdala after processing from associative cortical areas (McDonald,
1998). Sensory information is then transported to the basolateral nuclei of the amygdala.
This is where synapses are strengthened (or weakened) over time, producing CS-UCS
associations. The basolateral nuclei are connected to the central nucleus of the amygdala,
the primary fear production structure. This allows the newly learned fear association to
influence autonomic and motor centers involved in fear responses, including the
supplementary motor area (SMA; Davis, 2006; Kim & Jung, 2006; Pape & Pare, 2010).
The Supplementary Motor Area. While the amygdala cannot be directly
stimulated via TMS, TMS has been shown to modulate activity in brain regions well
beyond the locus of stimulation (Bohning et al., 2000; Cheeran, Koch, Stagg, Baig, &
Teo, 2010; Ji et al., 1998). For example, direct stimulation of the primary motor cortex
has been shown to affect the striatum (Strafella, Paus, Fraraccio, & Dagher, 2003). It is
therefore likely that stimulation to the SMA will induce combined action on cortical and
subcortical structures (stimulated transsynaptically). As noted above, afferent
connections exist from the SMA, partially responsible for integration of incoming
sensory information and subsequent behavioral responses, to the amygdaloid nucleus
(Davis, 2006; Kim & Jung, 2006; Jürgens, 1984). Thus, it is theorized that lowfrequency TMS to the SMA will aid in retraining the neural pathways between the SMA
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and the amygdala to fire less frequently, thereby decreasing fear and arousal associated
with amygdala activation.
Further support for the SMA’s role in PTSD comes in the form of a recent fMRI
investigation of posttraumatic flashbacks. Researchers found that the contrast of
flashbacks versus ordinary episodic memories in PTSD was associated with increased
activation in sensory and motor areas, including the SMA (Whalley, Kroes, Marijn, &
Huntley, 2013). It is also noteworthy that low-frequency stimulation to the SMA
decreases anxiety-related symptoms in disorders such as Obsessive Compulsive Disorder
(Mantovani, Simpson, Fallon, Rossi, & Lisanby, 2009). Finally, a study on working
memory deficits in PTSD showed activation in of the SMA in PTSD participants, but not
in controls, during working memory tasks (Shaw et al., 2009). While the role of the
SMA is not yet fully understood, these findings are further indication that, along with the
amygdala, the SMA is over-active in those with PTSD.
The Hippocampus. The hippocampus, a part of the limbic system that plays
important roles in the consolidation of information from short-term memory to long-term
memory, has been shown in animal studies to be essential in contextual fear conditioning,
and thus in PTSD. Communication between the hippocampus and the amygdala is both
direct and indirect through the prefrontal cortex (Pape and Pare, 2010). Thus, it is likely
that TMS can affect hippocampal activity through prefrontal cortex stimulation, and also
through stimulation of the SMA via pathways through the amygdala. Lesion studies have
shown that the hippocampus is required for the renewal of conditioned fear responses
(Kim & Jung, 2006; Maren, 2008). As such, it is probable that the hippocampus plays a
vital part in the maintenance of PTSD-associated fear and arousal.
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Most neuroimaging studies of the hippocampus in PTSD have examined
hippocampal structure rather than function. The primary finding is of decreased
hippocampal volumes in PTSD, compared to either trauma-exposed control subjects
(Bremner et al., 1995; Childress et al., 2013; Gurvits et al., 1996; Gilbertson et al., 2002)
or trauma-unexposed healthy subjects (Bremner et al., 2003; Childress et al., 2013;
Wignall et al., 2004; Winter & Irle, 2004). A few studies in the literature have examined
hippocampal function in PTSD. Blood flow in the hippocampus and parahippocampal
gyrus was significantly positively correlated with PTSD symptom severity (Shin et al.,
2004), which is consistent with findings of higher activity in the hippocampal region at
rest and during an auditory continuous performance task in those with PTSD (Sachinvala,
Kling, Suffin, & Cohen, 2000; Semple et al., 2000). Finally, a positive correlation was
found between flashback intensity and regional cerebral blood flow in the
perihippocampal region in patients with chronic PTSD (Ousch et al., 2009).
Other Notable Findings. In a study examining the effects of electrical
stimulation during brain surgery, it was found that the temporal cortex is yet another
brain region associated with the reliving of past experiences (Criteria B for PTSD;
Rosenberg et al., 2002). Further, a relation between flashbacks among patients with
PTSD and increased brain circuitry activity between the temporal and parieto-occipital
lobe has been identified. Using Magnetoencephalography (MEG), a non-invasive
technique that measures magnetic fields in the brain, researchers uncovered significant
differences between signals in the temporal and parieto-occipital right hemispheric areas,
particularly in the right superior temporal gyrus (Cohen et al., 2004). Later research has
not replicated these findings, but instead found increased brain circuitry activity in the
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sensory and motor areas, as mentioned previously (Whalley, Kroes, Marijn, & Huntley,
2013).
All of these various alterations in regional brain activity are thought to be related,
in part, to the distressing emotional symptoms associated with traumatic memories and
concomitant abnormalities in autonomic nervous system (ANS) function as well as in
endocrine function stemming from the hypothalmic-pituitary-adrenal (HPA) axis (Cohen,
et al., 2000; Yehuda, 2007). Thus, it is likely that those with PTSD also have increased
heart rates and elevated cortisol levels. As TMS is a focused, non-invasive treatment
procedure shown to stabilize neuron function and metabolism in the brain, is likely to
alleviate PTSD symptoms and normalize ANS and HPA axis function.
TMS Background
TMS was first applied to humans in the 1890s and found to induce phosphenes (a
sensation of flickering light), vertigo, and syncope. Scientists in the mid-20th century
used this early data to understand that the application of an electromagnetic coil to the
brain could induce visual changes and motor activity (George et al., 2007). By 1985, the
technology was being used by neurologists to study the conduction of motor impulses
between the central and peripheral nervous systems. Using TMS, Barker and colleagues
were able to stimulate the motor cortex of individuals and observe the subsequent motor
response (Barker, 1991). The fact that this was achieved painlessly and without the need
for loss of consciousness suggested a broader role for TMS in the field of
neurostimulation.
In 1987, while stimulating the motor cortex, Bickford was the first to illustrate an
improvement in mood in healthy subjects (Bickford, Guidi, Fortesque & Swenson, 1987).
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Neurologists and psychiatrists across Europe and the United States began to view TMS as
both a research tool and as a novel treatment modality. Groundbreaking works by Dr.
Pasqual-Leone at Harvard Medical School, Dr. Avery at the University of Washington,
Dr. George from the Medical College of South Carolina, Dr. Wassermann with the NIH,
and Drs. Lisanby and Mantovani at the New York State Psychiatric Institute have
demonstrated a breadth of evolving possibilities while offering significant data to support
the use of TMS for treatment of depression, anxiety disorders, and even psychosis
(George et al., 2007). When compared with other forms of neuromodulation such as
electroconvulsive therapy (ECT), deep brain stimulation (DBS), and vagal nerve
stimulation (VNS), TMS stands out as the least invasive in that it does not require
anesthesia, surgery or installed devices.
TMS is currently FDA approved for the treatment of major depression in people
who have failed at least one medication trial. High-frequency, repetitive TMS is thought
to balance out hypometabolism often seen with MDD and facilitate cortical responses in
the left prefrontal cortex (Pascual-Leone, Catalá, & Pascual-Leone, 1996; Pascual-Leone,
Valls-Solé , Wassermann, & Hallett, 1994). Its efficacy in populations of patients with
TRD has been demonstrated since the early 1990s. George et al. (1996), Pascual-Leone
et al. (1994), and Triggs et al. (1999) have all demonstrated a significant reduction in
scores on the Hamilton Depression Rating Scale (HAM-D) and Beck Depression
Inventory (BDI) in patients with severe TRD.
More recent studies have compared the efficacy of TMS with ECT (Grunhaus et
al., 2000; Schulze-Rauschenbach, Harms, Schlaepfer, Maier, Falkai & Wagner, 2005).
Both Grunhaus et al. and Schulze-Rauschenbach et al. demonstrated similar response
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rates between the two treatment modalities and underscored the improved side effect
profile of TMS when compared to ECT. In a double-blinded, sham-controlled2 study
with treatment-resistant patients, Avery et al. (2006) demonstrated significant response
and remission rates in participants receiving only 15 days of stimulation of the left
dorsolateral prefrontal cortex (DLPFC). Finally, the results of a recent NIMH-sponsored,
multi-center trial show TMS to be an efficacious treatment for TRD above and beyond
the traditional standard of care (George et al., 2010; Kim, Pesiridou, & O'Reardon, 2009).
These metabolic, biochemical, and self-reported mood changes have been correlated with
behavioral changes using functional neuroimaging. Whether or not long-term structural
changes occur is yet to be determined.
TMS Mechanism of Action
As opposed to other modalities of brain stimulation, such as electroconvulsive
therapy (ECT), deep brain stimulation (DBS), and vagal nerve stimulation (VNS), TMS
is non-invasive and relatively painless. The TMS device consists of an electrified
magnetic resonance imaging (MRI)-strength magnet and an iron-core, figure-eight coil.
A rapidly alternating magnetic field induces an electrical current that is discharged
through the coil. As per Faraday’s law, any rapidly alternating magnetic field can induce
an electrical current in a conducting substance (Serway, Moses, & Moyer, 2005). As
such, the charge is able to pass through the skull unimpeded and induce an electrical
current in the brain. The current depolarizes neuronal membranes and can then alter
2

Sham TMS is a term used to describe a range of procedures utilized as control conditions for TMS
treatment studies. Sham TMS can include the use of a special sham coil that is similar in all regards to a
TMS treatment coil, with the exception that it does not stimulate the cortex, thus double-blinding both the
treater and the patient. Sham TMS can also be used to describe tilting the coil 90 degrees off of the scalp or
stimulating at a different site. These options blind the patient to the condition but not the treater. All sham
TMS procedures discussed in the literature review for the present study refer to the former type of sham
condition; both treater and patient are blinded.
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neuronal firing with subsequent modulation of neurotransmitter release. This modulation
allows the strength of synapses between neurons to be increased or decreased depending
on frequency of the TMS (Huerta & Volpe, 2009). This process can have many
therapeutic effects, including alterations in mood, cognition, and behavior (Kluger &
Triggs, 2007; Lam, Chan, Wilkins-Ho & Yatham, 2008; Padberg & George, 2009).
Further research examining the mechanism of action of TMS has shown it has an effect
on gene expression (Cheeran, Koch, Stagg, Baig, & Teo, 2010), regional cerebral blood
flow (Speer et al., 2000), neurotransmission (Strafella, Paus, Barrett, & Dagher, 2001),
and neuroendocrine tone (Szuba et al., 2001). In essence, TMS exerts its clinical effect
by upregulating (high frequency TMS) or downregulating (low frequency TMS) neuronal
activity in a particular brain region (Kimbrell et al., 1999).
Effects of TMS on PTSD

Few studies have used TMS to treat PTSD. In the limited research available,
patients with difficult to treat and chronic PTSD have benefited from TMS above and
beyond the standard of care treatments available for this debilitating disorder (Boggio et
al., 2010). However, research thus far has utilized several different protocols to treat
PTSD. For instance, when repetitive TMS was applied to the left prefrontal cortex in
patients with co-morbid PTSD and depression (at 1Hz or 5 Hz at 80% of motor
threshold) there was a clinically significant antidepressant response in 9 out of the 12
patients, but researchers also found an improvement in core PTSD symptoms (Boggio et
al., 2010). The authors stated that there may be dissociation between treating mood and
core PTSD symptoms and it is therefore recommended that further research investigate
other protocols using repetitive TMS.
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In an earlier study, TMS (at 10 Hz and 80% of motor threshold) to the right
prefrontal cortex was administered to 24 patients with PTSD under double-blind,
placebo-controlled conditions, producing a significant reduction in PTSD
symptomatology (Cohen, 2004). The most recently reported study using TMS to treat
PTSD investigated the efficacy of 20 Hz repetitive TMS of either right or left dorsolateral
prefrontal cortex (DLPFC) as compared to sham TMS in 30 participants (10 in each
condition; Georgopoulos et al., 2010). Regardless of the frequency or intensity of the
stimulation used in these studies, it seems that patients are benefiting from the stimulation
either in improved mood, with high-frequency left-sided stimulation, or lower anxiety
levels, with low-frequency right-sided stimulation. Furthermore, there is preliminary
evidence that there is improvement in core PTSD symptoms above and beyond
improvement in mood and generalized anxiety when either side is treated.

Finally, a recent study examining TMS as a method of fear extinction in rats lends
support to the use of TMS for PTSD in humans. Baek, Chae, and Jeong (2012)
administered high-frequency (10 Hz) TMS to the rats with the coil placed approximately
3 mm anterior to bregma and set tangentially to the sagittal axis. A control group
received sham treatment. The rats treated with active TMS paired with a conditioned
stimulus (based on an UCS of electrical shock) during extinction showed an enhancement
in fear extinction over the sham group. Furthermore, this enhancement of fear extinction
remained after 24 hours without further stimulation. The authors concluded that this
finding suggests TMS paired with trauma-reminding stimuli enhances fear extinction.
Thus it is likely that TMS in conjunction with exposure therapy may be useful for
facilitating extinction memory in the treatment of PTSD.
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Effects of Combined TMS and Therapy on PTSD

Only one study has examined the combined effects of TMS and therapy to treat
PTSD (Ousch et al., 2009). Nine participants with chronic, treatment-refractory PTSD
were studied in a placebo-controlled, crossover design of imaginal exposure therapy with
low-frequency TMS (1 Hz) versus sham TMS. Participants received twenty 30-minute
sessions of active or sham TMS to the right DLPFC in the first phase of the study, and
then were switched to the remaining condition (sham or active) for the second phase.
Active TMS showed a larger effect size of improvement for hyperarousal symptoms
compared to sham. However, there was no difference between active TMS and sham for
intrusion and avoidance symptoms. Ousch and colleagues also examined 24-hour urine
and serum catecholamine and hormone levels, finding that increases in urinary
norepinephrine and serum T4 were greater with active TMS compared with sham TMS.
While these last findings did not have statistically significant p-values, they did show
large effect sizes (Cohen’s d = 0.88 and 1.43, respectively). It was not clear whether any
patients were below the clinical threshold for PTSD post-treatment.

Unlike the present study, Ousch et al. did not stimulate the SMA. Further, the
imaginal exposure procedure was different in that the participants could choose to speak
about any past traumatic memory, or could choose to be silent during TMS. There was
no information in the article detailing how many participants chose to be silent. The
protocol for the present asked the participants to continually speak of their most traumatic
military-related experience during each TMS session. It was believed that continual
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exposure to their most traumatic event will best activate the circuitry that is maintaining
their PTSD, and also wasthe best method for encouraging habituation to their trauma.

Effects of TMS on Neurocognitive Functioning
Executive Functioning. Results of studies examining pre- and post-TMS
neurocognitive functioning are limited, but consistently show no adverse effects, and
instead often demonstrate improved functioning (Bayan, 2014; Hufnagel, Claus,
Brunhoelzl, & Sudhop, 1993; Pascual-Leone et al., 1993; Wassermann, 1996; Martis et
al., 2003). In a study examining the effect of high-frequency TMS (20 Hz at 80% motor
threshold) on executive functioning, Moser and colleagues (2002) administered either
active (n = 9) or sham (n = 10) TMS targeted at the anterior portion of the left middle
frontal gyrus. Patients in the active TMS group improved significantly on a test of
cognitive flexibility and conceptual tracking (Trail Making Test–B). Triggs et al. (1999)
found improvements on tests of executive functioning and attention after 10 days of highfrequency (20 Hz) TMS over left DLPFC. A study by Martis et al. (2003) provides
further evidence of improved executive function post-TMS. TMS involved highfrequency left prefrontal stimulation delivered daily (Monday–Friday) using 10 Hz at
110% of motor threshold for 10 to 20 sessions. A battery of neurocognitive tests relevant
to attention, working memory-executive function, objective memory, and motor speed
were administered to participants before and after the TMS treatment. Following TMS,
participants showed significant improvements in working memory-executive function,
objective memory, and fine motor speed domains.
Memory. The Martis et al. study is only one of several findings indicating TMS
can improve memory function. Little et al. (2000) examined the cognitive effects of both
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low- (1 Hz) and high-frequency (20 Hz) TMS to the left DLPFC. Participants received
stimulation at 80% of motor threshold five days a week for two weeks. Results showed
modest, but significant improvements in visuo-spatial memory and verbal memory
following high-frequency TMS and improvements in verbal memory following lowfrequency TMS. Padberg et al. (1999) also found improvements in verbal memory scores
following five days of high-frequency (10 Hz) and low-frequency (0.3 Hz) TMS over the
left DLPFC. Lastly, Schulze-Rauschenbach and colleagues (2005) examined the
neurocognitive effects of both ECT and TMS in 30 patients. Each group received a mean
of 10 high-frequency (10 Hz) TMS sessions to the left DLPFC. Participants were
assessed for memory, executive functioning, and attention pre- and one week posttreatment. Results showed consistent or improved cognitive performance and alleviated
memory complaints for the TMS group. Further, TMS improved memory recall deficits
and decreased memory complaints for the ECT group.
While the neurocognitive effects of TMS discussed above involved participants
with TRD, these findings are relevant for those with PTSD as well because executive
functioning and memory have both shown impairment in this population (Uddo,
Vasterling, Brailey, & Sutker, 1993; Polak, Witteveen, Reitsma, & Olff, 2012).
Moreover, as no studies were found examining the neurocognitive effects of TMS for
PTSD, this is an area in which the knowledge base requires much expansion.
Imaginal Exposure Background
Anxiety and stress-related disorders can be treated by systematically exposing
patients to the objects and reminders of events that induce anxiety or distress
(Abramowitz, Deacon, & Whiteside, 2011; Echeburua, de Corral, Zubizarreta, &
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Sarasua, 1997; Pitman et al., 1996). Imaginal exposure is used to treat PTSD by
exposing patients to memories of the traumatic event in a safe and controlled setting,
thereby desensitizing them to the event and teaching them that they are no longer in
danger (Cahil & Foa, 2005; Foa, Hembree, & Rothbaum, 2007; Ruzek, Curran,
Friedman, & Gusman, 2002). Surprisingly, animal research indicates that autonomic
excitation, rather than relaxation and autonomic deactivation, improves the results of fear
extinction training (Cain, Blouin, & Barad, 2004), which forms the theoretical basis of
exposure therapy. Autonomic excitation has also been found to increase effectiveness of
anxiety disorder treatment in humans (Craske and Mystkowski, 2006).
Furthermore, exposure therapy is by far the most rigorously scientifically
supported treatment currently available for PTSD3. As mentioned previously, the APA
Society of Clinical Psychology (Division 12) lists exposure therapy as having ―strong
research support‖ based on its proven effectiveness in five separate randomized trials
(Foa et al., 1999; Foa et al., 2005; Foa, Rothbaum, Riggs, & Murdock, 1991; Keane,
Fairbank, Caddell & Zimering, 1989; Resick, Nishith, Weaver, Astin & Feuer, 2002).
Although other therapies have been deemed effective in the treatment of PTSD, exposure
therapy has been proven effective in more clinical trials than the other available
treatments. Expert Consensus Guidelines for the treatment of PTSD recommends
exposure therapy as the quickest and most effective psychotherapy for the treatment of
this disorder (Foa et al., 2009). In addition to exposure therapy’s proven effectiveness, it
is the most likely of the three established treatments for PTSD to produce autonomic
excitation, thus activating the TMS-targeted circuitry.

3

TMS is not currently FDA approved for the treatment of PTSD, and thus is not considered in this
treatment comparison.
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The Present Study

In general, clinical data are indicating that low frequency (i.e., 1 Hz) TMS
stimulation leads to a decrease in regional cerebral blood flow, dampening hyperactivity
seen in various brain regions (George et al., 1995; Kimbrell et al., 2002). Thus, it follows
that the brain regions found to be hyperactive in PTSD patients, such as the right DLPFC
and SMA, need to be dampened to normalize/stabilize the functioning of those neurons.
Additionally, it was hypothesized that activating the circuits responsible for the PTSD
symptoms, through imaginal exposure, while dampening their hyperactivity with TMS
may be a more effective and direct treatment than TMS or prolonged exposure alone.
However, there was no control group in the present study to examine this hypothesis. As
such, any inferences drawn from comparing results of the present protocol to results of
TMS or exposure protocols from previous studies are tentative and speculative at best.

Given these previous findings, the present study proposed to investigate the safety
and efficacy of TMS as a treatment modality for PTSD while brain circuits related to
PTSD symptoms are activated by the patient through repeated imaginal exposure. It was
further hypothesized that neuropsychological functioning, particularly in the areas of
memory and executive functioning, will improve following treatment.

Research Questions.
1. Is low-frequency TMS to the right DLPFC and the SMA combined with
prolonged imaginal exposure associated with reduced PTSD symptoms and
concomintant mood and anxiety symptoms (using the following scales: The
Treatment Outcome PTSD Scale, the PTSD Checklist-Military, the Beck
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Depression Inventory II, the Hamilton Depression Rating Scale, and the Beck
Anxiety Inventory) after 16 treatment sessions, and one week post-treatment?
2.

Is low-frequency TMS to the right DLPFC and SMA combined with
prolonged imaginal exposure associated with improved neurocognitive
functioning, including executive functioning, verbal memory, and visual
memory (using the following scales: CNS Vital Signs, the California Verbal
Learning Test Second Edition, the Rey Complex Figure Test, and the
Wisconsin Card Sorting Test) after 16 treatment sessions, and one week posttreatment?
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CHAPTER 2
METHOD AND PROCEDURE
Participants
Seven male participants between the ages of 22-55 who met DSM-IV criteria for
PTSD took part in the study. While the original goal was to recruit ten participants,
recruiting issues, including low response rates to fliers, brochures and radio
advertisements, as well as difficulties in recruiting collaboration with the local Veteran’s
Administration Medical Center resulted in a smaller than expected sample size for this
pilot study. It was required that the participants’ PTSD be the result of combat trauma.
Participants had failed to respond to at least one trial of medication or psychotherapy to
treat PTSD and had symptoms of PTSD for at least one year. As such, they were
considered to have chronic, treatment resistant PTSD. They were recruited from the
Eastern Virginia Medical School Department of Psychiatry by study investigators. Prior
to undergoing TMS treatment, a research team member informed each participant about
the research opportunity and explained the study details in full. If the participant was
interested in taking part, the clinical procedures were put in place, starting with the
informed consent.
Exclusionary Criteria
Exclusionary criteria included the following: being female, having an
uncontrolled significant medical illness (e.g., heart disease), pacemakers, cochlear
implants, metal objects in the head or eyes, a history of seizures, psychotic
disorders/symptoms, bi-polar disorder, active substance abuse/dependence issues, serious
suicidal thinking or intent, medications that would decrease seizure threshold, family
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history of epilepsy , bullet fragments or shrapnel within 30cm of the treatment coil, skull
defects, recent stroke/intracranial bleed, conditions which may increase intracranial
pressure, implanted medication pumps or intracardiac lines, ECT in the past 2 years, and
previous magnetic brain stimulation treatment such as TMS. Participants were permitted
to remain on medications that do not decrease seizure threshold, including psychotropic
medications, so as not to exacerbate any pre-existing conditions. Medication changes
were not made three months prior to the start of treatment or during the treatment
protocol with the following exceptions: over-the-counter melatonin was added to one
participant’s regimen to aid with severe insomnia, and one participant chose to taper off
his anti-depressant medication towards the end of treatment due to improved mood
symptoms.
Diagnostic Interview
Participants underwent a standardized diagnostic interview utilizing the Clinician
Administered PTSD Scale (CAPS) to confirm they met criteria for chronic PTSD. The
CAPS, widely considered the gold standard in assessing PTSD, is a 30-item structured
interview that is based on DSM-IV criteria for PTSD. A CAPS based on DSM-V criteria
had yet to be published at the start of the study. The first part of the CAPS asks the
participant to describe his traumatic event(s). If there are several combat-related events,
the participant was asked to discuss the event that caused him the most distress and
discomfort. That event was the primary focus of treatment. Symptoms were assessed
based on frequency: (0) Never; (1) Once or twice; (2) Once or twice a week; (3) Several
times a week; or (4) Daily or almost every day, and intensity of the associated distress or
discomfort: (0) None; (1) Mild, minimal distress or disruption of activities; (2)
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Moderate, distress clearly present but still manageable, some disruption of activities; (3)
Severe, considerable distress, difficulty dismissing memories, marked disruption of
activities; or (4) Extreme, incapacitating distress, cannot dismiss memories, unable to
continue activities). The CAPS may be used to assess a current or a lifetime PTSD
diagnosis, but for the purposes of this study, current symptomatology (during the past
month) was examined. The CAPS was also used to confirm that symptoms have been
present for more than one year, and thus that the participant’s PTSD was considered
chronic. The scale generally takes 45-60 minutes to administer and symptoms are
counted as ―present‖ if a frequency of ―1 or more‖ and an intensity of ―2 or more‖ are
selected. Severity scores can be calculated by the sum of the frequency and intensity
ratings (Blake et al., 1995). This interview was administered prior to the start of
treatment, but after the participant had consented.
Psychosocial Questionnaires
SociodemographicCharacteristics. Sociodemographic information was
collected at baseline and includes the following characteristics: age, education level,
marital status and race. This information was collected prior to the start of treatment.
PTSD Checklist-Military (PCL-M). The PCL-M is a 17-item self-report
measure of the 17 DSM-IV symptoms of PTSD. The PCL-M asks about symptoms in
response to "stressful military experiences." It is often used with active service members
and Veterans and has a variety of purposes, including screening individuals for PTSD,
diagnosing PTSD, and monitoring symptom change during and after treatment. It takes
approximately 5-10 minutes to complete a PCL-M, which uses a 5-point scale to rate
symptom severity over the past week (1 = ―not at all; 5 = ―extremely‖). Evidence
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suggests that a 5-10 point change represents reliable change (i.e., change not due to
chance) and a 10-20 point change represents clinically significant change (Blanchard,
Jones-Alexander, Buckley, & Forneris, 1996).
The test-retest reliability of the PCL-M is above the recommended level of α =
.70 after 2–3 days. The original investigation of the PCL-M in Vietnam and Persian Gulf
Veterans reported alpha values above .80 (Weathers, Litz, Herman, Huska & Keane,
1993). A later study of female Iraq and Afghanistan Veterans reported alpha values
above .75 (Owens, Herrera & Whitesell, 2009). Item-total correlations were more than
.40 in Vietnam and Persian Gulf Veterans (Weathers et al., 1993). In terms of convergent
validity, the PCL-M had a kappa of .64 with the PTSD section of the SCID in Vietnam
Veterans (Weathers et al., 1993). Clinician-rated (CAPS) and PCL-M self-reported
symptoms have been shown to be strongly related, Bs = 0.95 and 0.80 in the male and
female samples, respectively (Lunney, Schnurr & Cook, 2014). No studies were found
with the goal of assessing the PCL-M’s discriminant validity. This scale was
administered prior to treatment, post-treatment, and one week post-treatment.
Treatment Outcome PTSD Scale (TOP-8). The TOP-8 scale was developed as
a brief 8-item, clinician-administered scale for use in assessing responses to treatment in
patients with post-traumatic stress disorder. It utilizes the eight most commonly reported
symptoms of PTSD (Conner & Davidson, 1999). The instrument was developed from a
larger post-traumatic stress disorder evaluation scale, the Structured Interview for PTSD
(SIP), based on items which occurred frequently in the population and which responded
substantially to treatment across time. The measure takes about 5-10 minutes to
administer and uses a Likert-type scale to rate the extent to which each symptom has
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―troubled the person‖ during the past week (Conner & Davidson, 1999; Davidson &
Colket, 1997).
In a sample of males and females with chronic PTSD, internal consistency of the
TOP-8 indicated a Cronbach alpha of 0.73. Test-retest reliability gave a value of r =
0.884 (Connor & Davidson, 1999). In the same sample, convergent validity was strong.
For the self-rated Davidson Trauma Scale, the Pearson correlation coefficient was 0.91 (p
< .000), while for the Impact of Event Scale, the correlation was 0.89 (p < .000). The
TOP-8 has also been shown to have strong predictive validity. Using positive and
negative predictive values (PPV and NPV) and efficiency of the TOP-8, Connor and
Davidson (1999) found that the optimum score for rejection of a PTSD diagnosis was 8,
at which score the PPV was 0.86, NPV was 1.0, and efficiency was 0.93. For optimal
inclusion of patients with a diagnosis of PTSD, a score of 12 was found to be the
threshold; at that score, PPV was 1.0, NPV was 0.89, and efficiency was again 0.93. This
scale was administered prior to treatment, post-treatment, and one week post-treatment.
Beck Depression Inventory II (BDI-II). The BDI-II is a quantitative measure
of depression symptoms and level of severity of those symptoms (Beck, Steer, & Brown,
1996). This is a 21-item instrument with total scores ranging from 0-63. Items are rated
on a 0 to 3 rating scale with lower ratings indicating lower severity of symptoms during
the past two weeks (verbal anchors are specific to each question). Examples of
symptoms assessed are ―sadness‖, with responses ranging from I do not feel sad (0) to I
am so sad or unhappy that I cannot stand it (3), and ―loss of pleasure‖, with responses
ranging from I get as much pleasure as I ever did from the things I enjoy (0) to I can’t get
any pleasure from the things I used to enjoy (3).
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The BDI-II has been found to demonstrate high internal consistency reliability (α
= .93 among college students, α = .92 among outpatients; Beck et al., 1996). It has also
shown good convergent validity as BDI-II total scores are significantly related to the
State-Trait Anxiety Inventory Depression subscale (STAI-D) factor score (r = .76, p <
.001; Storch, Roberti, & Roth, 2004) and are more positively correlated with the
Symptom Cheklist-90-Revised version (SCL-90-R) Depression subscale (r = .89) than
the Anxiety subscale (r = .71) (Steer, Ball, Ranieri, & Beck, 1997). This measure will be
administered prior to treatment, post-treatment, and one week post-treatment.
Hamilton Depression Rating Scale (HAM-D). This instrument is used by
clinicians to assess the severity of depression in patients already diagnosed with
depression and is one of the most commonly used depression rating scales. It is a 17item instrument that assesses depressed mood, suicide, loss of interest, psycho-motor
retardation, agitation, gastro-intestinal symptoms, general somatic symptoms,
hypochondriasis, insight, and loss of weight. Items are rated on a scale ranging from three
to five options with lower ratings indicating lower severity of symptoms. Scores are
obtained by summing the response from each item.
As this instrument measures the clinician’s subjective assessment of the patient
as opposed to the patient’s self-description, it is subject to the biases of the administrator.
However, the inter-rater correlations, as reported by the test developer, ranged from 0.840.90 (Hamilton, 1960). A more recent meta-analysis carried out with 35 alpha
coefficients, obtained from 23 published research studies, showed a mean inter-rater
reliability of .79 (SD = 14; Lopez-Piña, Sánchez-Meca & Rosa-Alcázar, 2009).
Furthermore, the convergent validity between self-ratings of depression and HAM-D
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observer ratings has been found to be very high, with correlations exceeding 0.90 (BentHansen & Bech, 2011). This scale was administered prior to treatment, post-treatment,
and one week post-treatment.
Beck Anxiety Inventory (BAI). The BAI is a quantitative measure of anxiety
symptoms and level of severity of these symptoms (Beck, Brown, Epstein, & Steer,
1988). This is a 21 item, self-report questionnaire with scores ranging from 0-63.
Subjects indicate how much they have been bothered by anxiety symptoms over the past
4 weeks on a 0 (not at all) to 3 (Severely--I could barely stand it) rating scale. Unlike the
PCL-M and TOP-8, anxiety symptoms measured by the BAI are not PTSD specific.
Rather it is a more generalized anxiety measure.
The BAI has high internal consistency (α =.92) and test-retest reliability over 1
week, r = .75 (Beck et al., 1988). Zero-order correlational analyses have shown support
for convergent validity as well. The BAI total and subscale scores were found to be
moderately and significantly (Bonferroni’s alpha: .05/5 = .01) correlated with other selfreport anxiety scales (range, .35 to .69): the A-State, A-Trait, CCL-Anxiety, BSIAnxiety, and BSI-Somatization subscales (Osman, Kopper, Barrios, Osman & Wade,
1997). This measure will be administered prior to treatment, post-treatment, and one
week post-treatment.
Neuropsychological Assessment
All neuropsychological assessments were administered in an order such that
verbal tests did not overlap with other verbal tests and visual tests did not overlap with
other visual tests. This was to ensure that stimuli from any given assessment did not
interfere with performance on any other assessment.
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CNS Vital Signs. CNS Vital Signs (CNS-VS) is a compendium of computerbased neurocognitive tests. The psychometric characteristics, including test-retest
reliability, concurrent validity, and discriminant validity, of the tests in the CNS-VS
battery are reportedly similar to the characteristics of the conventional well-established
neuropsychological tests upon which they are. Test-retest reliability (Pearson’s r for
administrations separated by an average of 62 days) for the test components used in the
present study ranged from .31 (Stroop Test errors) to .87 (Stroop color-word reaction
time). Of the 25 test components examined, only five scores had correlation coefficients
lower than 0.6. Reliability coefficients for the five domain scores range from 0.65 to
0.87 (Gaultieri & Johnson, 2006). In terms of convergent validity, moderate correlations
were found between CNS-VS tests of memory and executive functioning and traditional
neuropsychological tests in these domains.

There is no evidence of practice effects

according to test developers. Further research indicated that repeated exposure within a
10 day interval did not lead to score improvements in a group of normal controls (Bayan,
2014). However, psychometric properties and potential practice effects of CNS-VS have
not been specifically examined in samples of men with PTSD. Cognitive testing will be
administered prior to treatment, post-treatment, and one week post-treatment. Testing
will include the Verbal Memory Domain, Visual Memory Domain, and Executive
Functioning Domain, as these are the most salient for the cognitive issues associated with
PTSD.
Verbal Memory Domain. The Verbal Memory Domain test assesses for verbal
learning, memory for words, word recognition, and immediate and delayed recall.
Fifteen words are presented, one by one, on the screen every two seconds. For immediate
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recognition, the participant has to identify those words nested among fifteen new words.
Then, after six more tests, there is a delayed recognition trial.
Visual Memory Domain. The Visual Memory Domain test assesses for visual
learning, memory for geometric shapes, geometric shapes recognition, and immediate
and delayed recall. Fifteen geometric figures are presented, one by one, on the screen.
For immediate recognition, the participant has to identify those figures nested among
fifteen new figures. Then, after five more tests, there is a delayed recognition trial.
Executive Functioning Domain. The Executive Functioning Domain consists of
two tests, the Stroop Test and the Shifting Attention Test. The Stroop Test assesses
simple reaction time, complex reaction time, inhibition/disinhibition, processing speed,
and importantly frontal or executive skills. The test has three parts. In the first part, the
words RED, YELLOW, BLUE, and GREEN (printed in black) appear at random on the
screen, and the participant presses the space bar as soon as the he sees the word. In the
second part, the words RED, YELLOW, BLUE, and GREEN appear on the screen,
printed in color. The participant is asked to press the space bar when the color of the
word matches what the word says. In the third part, the words RED, YELLOW, BLUE,
and GREEN appear on the screen, printed in color. The participant is asked to press the
space bar when the color of the word does not match what the word says.
The Shifting Attention Test assesses executive function, shifting sets, rapid
decision making with rules and categories, and reaction time. It is essentially a measure
of ability to shift from one instruction set to another quickly and accurately. Participants
are instructed to match geometric objects either by shape or by color. Three figures
appear on the screen, one on top and two on the bottom. The top figure is either a square
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or a circle. The bottom figures are a square and a circle. The figures are either red or
blue (mixed randomly). The participant is asked to match one of the bottom figures to
the top figure. The rules change at random (i.e., match the figures by shape for one trial,
and by color for the next).
California Verbal Learning Test Second Edition (CVLT-II). The California
Verbal Learning Test (CVLT) is a neuropsychological test that can be used to assess an
individual's verbal memory abilities, including immediate free recall, short-delay free
recall, short-delay cued recall, long-delay free recall, long-delay cued recall, and longdelay recognition. As such, the CVLT serves as a comprehensive measure of verbal
memory in that it incorporated learning and executive memory. For the present study, the
long delay free recall score was examined as this is the best measure of verbal memory
retrieval. The tester reads aloud a list containing sixteen common words, each of which
belongs to one of four categories: there are four pieces of furniture, four vegetable, four
ways of traveling, and four animals. The participant is then asked to recall as many of
these items as possible. First, the tester records how many items the subject remembers
over several repeated trials, which tests the participant’s learning curve. Next, the tester
gives a second list to see if the participant is able to keep the items from each list
separate, or if the two lists become confused. Finally, there is a delay of 20 minutes, and
then the tester again asks the participant to recall the initial list of words; this is the
measure examined in the present study. Because it measures several aspects of memory
and learning, the CVLT is popular as a neuropsychological test (Delis, Kramer, Kaplan,
& Ober, 2000).
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In a study evaluating 1-month test-retest reliability and practice effects associated
with the CVLT-II, results revealed generally large test-retest correlation coefficients for
the primary CVLT-II measures (range = 0.80–0.84). Reliable change indices were also
generated and applied to primary CVLT-II variables to determine the base rates of
significant improvements (range = 2–10%), declines (range = 0–7%), and stability (range
= 85–97%) in performance over time, supporting low potential for practice effects given
that is probable 85-97% of those tested will maintain a stable performance over time
(Woods, Delis, Scott, Kramer & Holdnack, 2006). However, it is again worth noting that
psychometric properties and potential practice effects of the CVLT-II have not been
specifically examined in samples of men with PTSD, which is a limiting factor for the
present study. The CVLT takes approximately 35 minutes to administer and was given
prior to treatment, post-treatment and one week post-treatment.
Rey Complex Figure Test (RCFT). Results of factor analysis suggest that the
RCFT captures five domains of neuropsychological functioning: visuospatial recall
memory, visuospatial recognition memory, response bias, processing speed, and
visuospatial constructional ability (Meyers & Meyers, 1995). For the present study,
visuospatial recall was the measure examined as it is the best indicator of visual memory
retrieval. The RCFT serves as a more comprehensive measure of visual memory as it
incorporates executive memory in that visual stimuli have to be recalled and arranged in
a specific configuration. Participants are first asked to copy a complex line drawing, and
are subsequently asked to recall as much of the drawing as they can after a 3-minute
delay, and then after a 30-minute delay. The recognition trial asks participants to select
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designs that were part of the initial figure from 24 designs, some of which were part of
the initial figure and some of which were not (Meyers & Meyers, 1995).
Numerous studies have found the RCFT to have good interrater reliability for all
trials, including the delayed recall trial used in the present study, (r = 0.92 p < 0.0001,
Luzzi et al., 2011; (r = .98, df = 85, p < .001, Loring, Martin, Meador & Lee, 1990; r =
.96, p < .001, Berry , Allen & Schmitt, 2007), which is of great importance for this
measure as there is a subjective element to the scoring. Moderate test-retest reliability
has been observed for the delayed recall condition (r = .59, p < .001, Berry et al., 2007).
Validity investigations have focused primarily on the RCFT’s ability to detect deficits of
visuo-spatial memory, thought to result from lesions of the right temporal lobe (Milner,
1975). Binder (1982) found that right hemisphere stroke patients scored significantly
below left hemisphere patients on RCFT recall, suggesting the measure is sensitive to
visuo-spatial memory deficits rather than general memory deficits. With regard to the
RCFT as a general memory assessment, it has been found that, for patients matched on
demographic characteristics, RCFT scores are significantly lower for Alzheimer’s
patients than for controls (Berry et al., 2007). In terms of practice effects, Levine, Miller,
Becker, Selenes and Cohen (2004) found a mean increase of 2.3 points at re-assessment,
with the mean time interval being 251 days. The sample consisted of 478 healthy men.
While the increase in score was minimal, the time interval was significantly longer than
in the present study. Once again, it is also important to mention that psychometric
properties and potential practice effects of the RCFT have not been specifically examined
in samples of men with PTSD. The RCFT takes approximately 35 minutes to administer
and was administered prior to treatment, post-treatment and one week post-treatment.
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Wisconsin Card Sorting Test (WCST). The WCST was developed to assess
abstract reasoning and ability to shift cognitive strategies in response to environmental
changes. Unlike other tests of abstraction, the WCST provides objective measures not
only of overall ability, but also of particular sources of difficulty--e.g., inefficient initial
conceptualization, perseveration, failure to maintain set, and inefficient learning across
several stages of the test. The test uses stimulus and response cards that show various
forms in various colors and numbers. It requires the participant to sort the cards
according to different principles (i.e., by color, form, or number). As the test progresses,
there are unannounced shifts in the sorting principle which require the participant to alter
his approach.
The developers of the test report generalizability coefficients of .37 to .72 for the
various measures of the test (Heaton, 1993). Test-retest reliability findings are mixed,
with the test proving much more reliable in clinical samples with initial scores that are
below average than in those with average or above average initial scores (Strauss,
Sherman & Spreen, 2006). Average correlations on test measures administered a median
of 12 days apart was .64 in a sample of patients with broadly average scores at first
administration (Ingram, Greve, Ingram & Soukup, 1999). The literature is also mixed on
practice effects for the WCST. Basso, Bornstein and Lang (1999) calculated reliable
change indices using the standard error of prediction to estimate the range of change in
scores over a 12 month period that might be expected while accounting for measurement
error and practice effects. They found a fairly wide range of retest scores that may fall
within a 90% confidence interval and still reflect measurement error rather than
meaningful change. However, Tate, Perdices and Maggiotto (1998) reported generally
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strong stability coefficients in the context of no significant change in performance over
time in normal individuals. Again, it is important to mention that psychometric
properties and potential practice effects of the WCST have not been specifically
examined in samples of men with PTSD. Thus, results on neurocognitive measures in the
present study must be interpreted with caution. There is considerable shared variance
between the WCST and other tests of executive functioning, particularly tests of
conceptual reasoning, but research also demonstrates that different executive functioning
tests measure different abilities within conceptual reasoning. For instance, Perrine (1993)
found the WCST to share 30% variance with the Category Test, which is substantial, but
it is clear they are measuring separate factors to some extent. Perrine observed that
unlike the Category Test, the WCST is not merely a concept identification test, but also
an attribute identification test. Numerous studies have found, through factor analysis,
that the WCST is primarily a measure of shifting ability, supporting the commonly held
view that the WCST is an executive task (Fisk & Sharp, 2004; Miyake, Emerson &
Friedman, 1999, Miyake et al., 2000). Thus, it seems WCST is a test of one or possibly a
few very important aspects of executive functioning, but not ―executive functioning‖ as a
whole. It seems unlikely that a single measure could assess all of executive functioning
as it encompasses such a myriad of abilities, but the CNSVS Executive Functioning
Domain score is more general than most because it is derived from several tests
measuring different aspects of executive functioning. The test takes approximately 30
minutes to administer (Nelson, 1976). This test was administered prior to treatment,
post-treatment and one week post-treatment.
Aparatus
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The Neuronetics NeuroStar Transcranial Magnetic Stimulation (TMS) System
(Model Number 81-00315-000; Serial Number 0276) was used in the clinical procedures.
It is a Class II medical device that produces pulsed magnetic fields of short duration.
These rapidly alternating magnetic fields induce electrical currents within targeted
regions of the cortex associated with physiological and functional brain changes
(Horvath, Mathews, Demitrack, & Pascual-Leone, 2012).
Clinical Procedures
TMS Treatment. For the present study, participants received 16 sessions (one 1hour session per day) of low frequency (1Hz) TMS over a 5 week period; 1session per
day for 10 consecutive days, excluding weekends, and the remaining 6 sessions as a 3
week taper (three in week 3, two in week 4, and one in week 5). Table 1 details the
timing and clinical procedures of the protocol. The Neurostar coil was first positioned
above the right DLPFC (generally thought to be approximately 5cm anterior to an
individual’s pre-central gyrus or motor strip), then repositioned to the supplementary
motor area for the remaining half of the treatment. During the treatment, the coil was held
in place on the skull; it discharged its magnetic field at a rate, frequency and duration that
was specific to each patient and his prescribed treatment. Because the magnetic field is
extremely focused – generally penetrating no more than 2-3 cm of cortex, the induced
electrical current is also highly specific in terms of location.
The treatment protocol included the following parameters: 2400 pulses/session
(1200 pulses above the right DLPFC and 1200 at the supplementary motor area), 1 pulse
per second at 110% of the Motor Threshold (MT) intensity for the right DLPFC and
100% for the supplementary motor area. The initial treatment session involved the
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determination of a patient’s motor threshold (the lowest amount of stimulation required to
produce a consistent motor response). This step allowed for the treatment to be tailored
to each individual thus avoiding over- or under-stimulating. MT differences between
individuals are related to age, gender and cortical excitability, among other factors
(Lisanby, Kinnunen, & Crupian, 2002; Wassermann, 1996). Each TMS treatment lasted
for 40 minutes, with each brain area treated for 20 minutes.
Imaginal Exposure Treatment. Prolonged imaginal exposure was administered
while the participants were seated in the apparatus, concurrently with TMS treatment.
After each TMS/exposure session was finished, an additional 20 minutes was spent
processing the patient’s reactions to the prolonged exposure. Thus, each session was
approximately one hour. The protocol for imaginal exposure followed the current PTSD
guidelines for Prolonged Exposure Therapy (VA, 2009), but did not include the ―at
home‖ portion of the treatment as that would be difficult to standardize. The
standardized dialogue for the imaginal exposure procedure was adapted from Edna Foa’s
protocol for treating PTSD with exposure (Foa et al., 2007). The goal of this therapy is to
emphasize repetitive expression of traumatic memories to facilitate five primary goals
(Foa, 2007; Ruzek et al., 2002). According to Foa et al. (2007) and the Veterans
Administration (2009), first, repeatedly recalling the memory will help the participant to
organize the memory and get new perspective about what happened during and after the
trauma. Second, repeated revisiting of the trauma helps the participant to differentiate
between ―remembering‖ the traumatic event and ―being re-traumatized.‖ Third, repeated
imaginal exposure to the trauma memory for an extended period of time lowers anxiety
through habituation. Fourth, repeatedly revisiting the memory in imagination promotes
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differentiation between the event and similar events and thereby decreases the
generalization of fear from the specific trauma to similar but safe situations. Fifth,
repeatedly recounting the memory enhances the participant’s sense of self-control and
personal competence. The participant feels progressively better about himself as he stops
avoiding and masters his fears. The therapy consists of three parts, each introduced
separately over the course of treatment: education, breathing, and talking through the
trauma.
The participants were educated about TMS to understand the goals of the
treatment in relation to their symptoms. This provided a foundation for the next sessions.
As per Foa et al.’s (2007) protocol, the second part of therapy consisted of breathing
skills to aid the participant in learning how to relax in order to manage immediate stress.
Finally, the imaginal exposure procedure was used to guide participants in talking
through their traumatic event. The traumatic event addressed was determined during the
CAPS, as described above. Again, the goal of this part of the therapy was to help the
participant reduce negative thoughts and perceptions of danger associated with the
trauma and increase perceived self-control of memories. During the TMS treatment
sessions, the clinician encouraged the participants to express the trauma they experienced
though imaginal exposure. Following TMS, the imaginal exposure session was
processed according to Prolonged Exposure guidelines (Foa et al., 2007).
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Table 1
Timing and Clinical Procedures of the Protocol
Pre-Tx
CAPS
Psychoeducation
Breathing
Retraining
Psychosocial
Assessments
Cognitive
Assessments

Session 1
MT
Determination
st
1 TMS Tx

Sessions 2-10
Daily TMS for 2
weeks
PE concurrent
with TMS

Sessions 11-15
TMS Taper over 3
weeks
PE concurrent with
TMS

Session 16
Final TMS
Session
Psychosocial
Assessments
Cognitive
Assessments

1 Week Post Tx
Psychosocial
Assessments
Cognitive
Assessments
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Design and Data Analyses
In the present study, change was assessed over time for the same group of
participants in a repeated measures observational design. The form of the design is A
(baseline), B (measures taken post-treatment, the day of the last session), A (removal of
treatment one week post), with ―A‖ representing the control condition, and ―B‖
representing the treatment condition. The design was chosen for several reasons,
including limited funding, which necessitates a limited number of participants, but also
because a small pilot study is warranted to determine if the proposed treatment is viable,
prior to a larger RCT.
This repeated measures design reduces the variance of estimates of treatmenteffects, allowing statistical inference to be made with a small sample size. A power
analysis using G*Power 3.1indicated that a minimum of 5 participants are needed to
obtain a significant result for PTSD symptom change following TMS, with a large effect
size. Effect size inputs were from Berlim and Van den Eynde’s (2012) meta-analysis of
studies using TMS to the DLPFC for treatment of PTSD. They found large effect sizes
for active TMS (versus sham) for self-reported PTSD symptoms (Hedge’s g = 1.91),
depression symptoms (Hedge’s g = 0.85) and anxiety symptoms (Hedge’s g = 1.24).
Although effect size inputs for depression and non-PTSD specific anxiety were quite
large, they were marginally smaller than the effect size input for PTSD symptoms.
Accordingly, the power analyses did indicate that this study may be underpowered to
detect change in depression and non-PTSD anxiety symptoms. A further power analysis
indicated that a minimum of 4 participants are needed to detect changes in executive
functioning following TMS to the DLPFC. Effect size inputs were from Bayan’s (2014)
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study examining cognitive changes following TMS in a depressed sample. Executive
functioning was measured using CNS-VS with an effect size of 2p = 0.781. While effect
sizes for change in executive functioning in a sample with PTSD would be most
appropriate, this was not found in the literature. As such, it may be that the present study
is underpowered to detect such effects. There were no articles found examining changes
in verbal and visual memory following TMS to the DLPFC and/or the SMA, in a sample
with PTSD. As such, effect sizes were calculated from Martis et al.’s (2003) means and
standard deviations in their study examining changes in verbal and visual memory
following TMS to the DLPFC in a depressed sample. Effect size inputs were Cohen’s d
= 0.38 for delayed visual memory and Cohen’s d = 0.73 for delayed verbal memory.
Power analyses indicated that the present study may be underpowered to detect changes
in verbal and visual memory post-TMS. Further, as inputs for power analyses of
cognitive measures are from a TMS treatment sample with depression rather than with
PTSD, all statistical results must be interpreted with caution. When a study is
underpowered, this can result in higher likelihood of Type II error, or failing to detect an
effect when it is present. An underpowered study can also result in a larger variance of
the estimates of the parameter being estimated. In other words, the sampling distribution
of sample means is wide. This reflects the general phenomenon that studies with low
power have a higher chance of a large effect size than studies with high power. In
particular, when there is a Type I error (falsely rejecting the null hypothesis), the effect
will appear to be stronger with a small sample size (lower power) than with a large
sample size (higher power). This may suggest an effect that is not there. As such, results
of clinical significance will be granted more weight than results of statistical significance.
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This design was further chosen for the sake of efficiency, as it allows the study to
be completed more quickly. Finally, this design was chosen for its longitudinal analysis.
Repeated measures designs allow one to monitor how participants change over time,
which is certainly relevant as client change over time is the foundation of clinical work.
This design does however have some limitations due to its not being a randomized
controlled trial, such as the possibility of maturation; influence of events outside the
experiment that may change responses between measures; the risk of order effects, such
as practice, boredom, or fatigue; the risk of expectancy bias. There is also the risk of
unintended treatment provider influence (e.g., rapport between patient and treatment
provider may be stronger in the present study than in the current standard of care due to
treatment being provided every day as opposed to once or twice a week).
Descriptive statistics (percentages, means, and standard deviations) were used to
describe patient characteristics (e.g., age, education level, race, and marital status). To
measure efficacy of TMS, repeated measures ANOVAs were used to examine changes in
PTSD symptoms, depression symptoms, anxiety symptoms, and cognitive functioning to
TMS treatments over time. Although the sample size is quite small, this does not violate
the assumptions of an ANOVA, as minimum sample size for a one-way ANOVA F-test
is one more than the number of groups (Boos & Hughs-Oliver, 2000; Bradley, 1980).
However, with a sample size of seven, a visual plot is likely too scarce to prove a normal
distribution. Thus, results of the ANOVAs should be interpreted with caution. The
omnibus ANOVAs were followed by simple contrast post hoc comparisons to compare
within-subjects factor - time points to respective baseline measures. In previous studies
treating PTSD with TMS to the right DLPFC, decreases in PTSD symptoms ranged from
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a 29.3% decrease to a 36.9% decrease when measuring symptoms with the PCL (Boggio
et al., 2010; Cohen et al., 2004). The hope is to replicate or improve upon these results as
this study has a similar sample size and a somewhat similar protocol to said studies, but
with the addition of prolonged exposure treatment. Again, as mentioned above,
comparisons across studies are merely speculative and not meant as a substitute for a
control group in the present study. Additionally, a 5-10 point decrease on the PCL is
typically considered statistically significant, while a 10-20 point decrease is considered
clinically significant (Blanchard et al., 1996). For all other measures used, a change in 1
standard deviation would indicate clinical benefit.
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CHAPTER 3
RESULTS
Sample Demographics
In order to characterize the sample, descriptive statistics were conducted. Seven
total patients completed a course of combined imaginal exposure and TMS for chronic,
treatment-resistant PTSD. As seen in Table 2, the total mean age of the 7 patients was
39.29 with a standard deviation of 6.45. The sample was comprised of male OEF/OIF
combat Veterans of Caucasian (n = 5), African American (n = 1) and Bi-racial (n = 1)
background. Patient education level fell between a high school degree and a master’s
degree with 57% of the sample (n = 4) completing some college but no college degree.
All patients met DSM-IV criteria for chronic Post Traumatic Stress Disorder as per the
CAPS interview.
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Table 2
Demographic Data
Min
31

Max
47

n

%

Gender
Male

7

100.0

Ethnicity
Caucasian
African American
Bi-racial

5
1
1

71.4
14.3
14.3

Marital Status
Married
Divorced
Separated
Single

3
3
1
0

42.9
42.9
14.3
0

Highest Education
HS Diploma
Some College
Associate’s Degree
Bachelor’s Degree
Master’s Degree
Total

1
4
0
1
1
7

14.3
57.1
0
14.3
14.3

Age

̅
39.29

SD
6.45
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Total scores on measures of PTSD symptom severity, depression symptom
severity and anxiety symptom severity, as well as total scores on neurocognitive
measures of executive functioning, verbal memory and visual memory were collected at
pre-treatment, immediately post-treatment (same day) and one week post-treatment.
Scores at these three time points were then compared using repeated measures omnibus
ANOVAs followed by post-hoc analyses. Clinical significance was also calculated to
help determine the practical importance of the treatment effects.
Research Question 1
Is low-frequency TMS to the right DLPFC and the SMA combined with
prolonged imaginal exposure associated with reduced PTSD symptoms and
concomitant mood and anxiety symptoms (using the following scales: The PTSD
Checklist-Military [PCL-M], the Treatment Outcome PTSD Scale [TOP-8], the
Beck Depression Inventory II [BDI-II], the Hamilton Depression Rating Scale
[HAM-D], and the Beck Anxiety Inventory [BAI]) after 16 treatment sessions? If
symptoms are reduced, are reductions maintained at one week post-treatment?
Five independent repeated measures ANOVAs were conducted to compare mean
total score differences for PTSD symptoms and associated mood and anxiety symptoms
(using the total scores for the PCL-M and TOP-8 to measure PTSD symptom severity;
the BDI-II and HAM-D to measure depressive symptom severity; and the BAI to
measure general anxiety symptom severity) from pre-treatment to post-treatment and one
week post-treatment. The one-way repeated measures ANOVA comparing total mean
scores on the PCL-M at each time point revealed statistically significant differences
across test administrations, F(2,12) = 15.49, p < .001, 2p = 0.721, 90% CI [0.354,
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0.806]4. Tukey’s HSD post-hoc analyses further revealed that both the post-treatment
PCL-M total mean score (38.71 ± 13.91) and the one week post-treatment mean score
(33.29 ± 16.62) were significantly lower (reduced PTSD symptom severity) than the pretreatment mean score (64.71 ± 12.62; p < .05). While there was a further slight reduction
in mean score from post-treatment to one week post-treatment, this was not statistically
significant. Thus, in terms of PTSD symptom severity as measured by the PCL-M,
statistically significant reductions were found after 16 sessions of treatment, with those
reductions remaining stable at one week post-treatment (Figure 1). This represents a
51.4% decrease in PTSD symptoms. Notably, clinically significant reductions were also
found. All patients demonstrated clinically significant reductions (more than 10-point
change) in PTSD symptoms from pre-treatment to post-treatment on the PCL-M, with
86% of the sample falling below the 50-point cutoff score for likely a PTSD diagnosis by
one week post-treatment.
Similarly, the second one-way repeated measures ANOVA showed a significant
decrease in TOP-8 mean total scores across test administrations, F(2,12) = 16.03, p <
.001, 2p = 0.728, 90% CI [0.366, 0.811]. Tukey’s HSD post-hoc analyses again revealed
that both the post-treatment mean score (11.57 ± 6.21) and the one week post-treatment
mean score (11.14 ± 8.84) were significantly lower (reduced PTSD symptom severity)
than the pre- treatment mean score (24.00 ± 5.23; p < .05). Once again, there was a slight
reduction in mean score from post-treatment to one week post-treatment, but this was not
statistically significant. And so, in terms of PTSD symptoms as measured by the TOP-8,
A 90% rather than 95% confidence interval was used for  p for the following reason: While a 95% CI is
traditionally reported with Cohen’s d, Cohen’s d can be both positive and negative. η² is squared, and can
therefore only be positive. If a 95% CI is calculated, it may result in situations where the confidence
interval includes values less than 0. Furthermore, a 95% CI around Cohen's d equals a 90% CI around η²
for exactly the same test, (Steigler, 2004).
4

2
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significant reductions were found after 16 sessions of treatment, with those reductions
remaining stable at one week post-treatment (Figure 2).
The third and fourth one-way repeated measures ANOVAs comparing pretreatment, post-treatment and one week post-treatment mean scores for severity of
depressive symptoms determined a significant decrease in BDI-II mean total scores,
F(2,12) = 20.56, p < .001, 2p = 0.774, 90% CI [0.452, 0.843] and in HAM-D mean total
scores, F(2,12) = 25.92, p < .001, 2p = 0.812, 90% CI [0.529, 0.869]. Tukey’s HSD
post-hoc analyses revealed that both the post-treatment mean score (12.57 ± 10.31) and
the one week post-treatment mean score (8.57 ± 8.83) for the BDI-II were significantly
lower (reduced depressive symptom severity) than the pre- treatment mean score (33.29 ±
8.79; p < .05). While there was a further reduction in mean score from post-treatment to
one week post-treatment, this was not statistically significant. In terms of clinical
significance, 100% of the sample demonstrated clinically significant reductions (as
measured by 1 SD in change from the pre-treatment measure) in depressive symptoms
from pre-treatment to post-treatment on the BDI-II. At pre-treatment 57% of patients had
severe levels of depressive symptoms as per the BDI-II and the remaining 43% had
moderate levels of depressive symptoms. By one week post-treatment, 14% of the
sample had moderate levels of depressive symptoms, with 86% of the sample falling
below the 14-point cutoff score for mild levels of depressive symptoms.
The same pattern emerged with Tukey’s post-hoc analyses of the HAM-D mean
total scores, with both the post-treatment mean score (9.43 ± 5.29) and the one week
post-treatment mean score (7.57 ± 4.61) being significantly lower (reduced depressive
symptom severity) than the pre-treatment mean score (24.00 ± 5.23; p < .05). Again,
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while there was a further reduction in mean score from post-treatment to one week posttreatment, this was not statistically significant. Thus, in terms of depressive symptom
severity as measured by the BDI-II and the HAM-D, significant reductions were found
after 16 sessions of treatment, with those reductions remaining stable at one week posttreatment (Figures 3 and 4).
Finally, prior to the fifth one-way repeated measures ANOVA of mean total BAI
scores, winsoration5 was required for the one week post-treatment data to eliminate a
major outlier that was skewing the data. A calculation of the interquartile range was used
to determine that one value for the BAI post-treatment measure was beyond the outer
fence of the upper quartile, and thus was a major outlier. As this value was such an
extreme outlier, and as the patient who reported this value experienced a significant
adverse personal event between his post-treatment BAI score (25 points) and his one
week post-treatment BAI score (47 points), his one week post-treatment score was
winsorized to bring it back into range with the other one week post-treatment scores.
Following winsorization of the data, a one-way repeated measures ANOVA
showed a significant decrease in anxiety symptom severity as measured by BAI mean
total scores across test administrations, F(2,12) = 7.71, p = .007, 2p = 0.562, 90% CI
[0.135, 0.697]6. Tukey’s HSD post-hoc analyses further revealed that both the posttreatment mean score (11.71 ± 8.83) and the one week post-treatment mean score (7.29 ±

5

Winsorising is a commonly used transformation of statistics that limits extreme values in the data to
reduce the effect of possibly spurious outliers.
6
Prior to winsoration, the omnibus ANOVA for BAI mean total scores did not show a significant decrease
2
in anxiety symptom severity across test administrations, F(2,12) = 3.56, p = .061,  p = 0.372. However, a
one-way repeated measures ANOVA comparing only pre- and post-treatment mean total scores revealed a
significant decrease in mean total BAI scores form pre- to post-treatment, F(1,6) = 6.73, p < .05, 2p =
.529, thus indicating that the outlier in the one week post-treatment measure was likely skewing the results
of the omnibus ANOVA.
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5.02) were significantly lower (reduced anxiety) than the pre- treatment mean score
(25.57 ± 14.93; p < .05). While there was a further slight reduction in mean score from
post-treatment to one week post-treatment, this was not statistically significant. Thus, in
terms of non-PTSD specific anxiety symptom severity as measured by the BAI,
significant reductions were found after 16 sessions of treatment, with those reductions
remaining stable at one week post-treatment (Figure 5). With regard to clinical
significance, 43% of the sample demonstrated clinically significant reductions (as
measured by 1 SD in change from the pre-treatment measure) in anxiety symptoms from
pre-treatment to post-treatment on the BAI. Means, standard deviations and confidence
intervals for PCL-M, TOP-8, BDI-II, HAM-D and BAI pre-treatment, post-treatment and
one week post-treatment scores are reported in Table 3.
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Table 3
Mean Total Scores, Standard Deviations (SD) and 95% Confidence Intervals [95% CI]
at Pre-Treatment, Post-Treatment and One Week Post-Treatment for PTSD, Depression
and Anxiety Symptoms
Pre-Treatment
Mean (SD)
[95% CI]

Post-Treatment
Mean (SD)
[95% CI]

One Week Post
Mean (SD)
[95% CI]

PCL-M

64.71 (12.62)
[53.04, 76.39]

38.71 (13.91)
[25.85, 51.58]

33.29 (16.62)
[17.91, 48.66]

TOP-8

24.00 (5.23)
[19.17, 28.84]

11.57 (6.21)
[5.82, 17.32]

11.14 (8.84)
[2.97, 19.32]

BDI-II

33.29 (8.79)
[25.16, 41.41]

12.75 (10.31)
[3.04, 22.11]

8.57 (8.83)
[0.41, 16.74]

HAM-D

25.14 (7.97)
[17.77, 32.51]

9.43 (5.29)
[4.54, 14.32]

7.57 (4.61)
[3.31, 11.84]

25.57 (14.93)
[11.76, 39.38]

11.71(8.83)
[3.55, 19.38]

7.29 (5.02)
[2.64, 11.93]

PTSD Symptoms

Depression Symptoms

Anxiety Symptoms
BAI
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PCL-M Total Score Means
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Figure 1. PCL-M 3-Time Point Total Score Means
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Figure 2. TOP-8 3-Time Point Total Score Means
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BDI-II Total Score Means
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Figure 3. BDI-II 3-Time Point Total Score Means

HAM-D Total Score Means

35
30
25
20
15
10
5

0
Pre-Treatment

Post-Treatment

Figure 4. HAM-D 3-Time Point Total Score Means
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BAI Total Score Means
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Figure 5. BAI 3-Time Point Total Score Means

One Week Post
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Research Question 2
Is low-frequency TMS to the right DLPFC and SMA combined with
prolonged imaginal exposure associated with improved neurocognitive functioning,
including executive functioning, verbal memory and visual memory (using the
following scales: CNS Vital Signs [CNS-VS], the California Verbal Learning TestSecond Edition [CVLT-II], the Rey Complex Figure Test [RCFT], and the
Wisconsin Card Sorting Test [WCST]) after 16 treatment sessions? If improved
cognitive functioning is observed, are gains maintained one week post-treatment?
Prior to carrying out the analyses for research question 2, correlations and Chisquare analyses were conducted to assess for any appropriate covariates to be included in
the repeated measures ANOVA analyses. In order to be excluded from the analyses,
variables must covary with treatment measures across all three time points. Kendall’s
Tau-b correlations7 were conducted between potential covariates and each cognitive test
(CNS-VS Indices, CVLT-II, RCFT, and WCST) at each time point (pre-treatment, posttreatment, and 1 week post-treatment). Bi-serial correlations were conducted for all
continuous variables (e.g., age, baseline PCL-M score, baseline TOP-8 score, baseline
BDI-II score, baseline HAM-D score, and baseline BAI score), while categorical and
ordinal variables (e.g., race and education level) were tested using Chi-square analyses.
Results identified no significant covariates across all three time points for any of the
neurocognitive measures As no variables covaried significantly with treatment measures

7

Kendall’s tau-b correlations were chosen as they are the most conservative and resilient to the effects of a
small sample size. Although, even Kendall’s tau is most stable with a sample size of at least 10. As such,
correlations should be interpreted with caution due to possible instability. For a sample size of 7, the
critical value of tau for α = .05 is .6190 (Abdi, 2007).
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across all three time points, their variance was not excluded from the analyses.
Correlations are listed in Tables 6 and 7 in the Appendix.
Research question 2 examines whether a course of TMS administered
concurrently with prolonged imaginal exposure for the treatment of PTSD is associated
with changes in neurocognitive scores by end of treatment. CNS-VS was used to assess
cognition at pre-treatment, post-treatment and one week post-treatment. Additionally,
more traditional, well-established neuropsychological tests were used to examine the
domains of executive functioning (WCST) and memory (CVLT-II and RCFT) as
research indicates PTSD-associated deficits in these domains (Uddo et al., 1993; Polak et
al., 2012).
Three independent repeated measures ANOVAs were conducted to compare
standard mean score differences for three CNS-VS cognitive domains (Executive
Functioning, Verbal Memory and Visual Memory) for pre-treatment, post-treatment and
one week post-treatment time-points. The one-way repeated measures ANOVA for
Executive Functioning Domain standard scores revealed statistically significant
differences across test administrations, F(2,12) = 4.79, p < .05, 2p = .444, 90% CI
[0.032, 0.612]. Tukey’s HSD post-hoc analyses revealed that the post-treatment mean
score (91.29 ± 34.35) was not significantly higher than the pre-treatment mean score
(71.57 ± 31.80). However, the one week post-treatment mean score (98.57 ± 35.41) was
significantly higher than the pre-treatment mean score (p < .05). While there was a slight
improvement in performance from post-treatment to one week post-treatment, this
difference was not statistically significant. Thus, in terms of executive functioning as
measured by CNS-VS, significant improvement was observed, but not until one week
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post-treatment (Figure 6).
One-way repeated measures ANOVAs examining the CNS Vital Signs Verbal
Memory and Visual Memory Domains revealed no statistically significant differences
across test administrations for either verbal memory, F(2,12) = 0.52 p = .607, 2p = .080,
90% CI [0.000, 0.266] or visual memory, F(2,12) = 0.05 p = .947, 2p = .009, 90% CI
[0.000, 0.101] (Figures 7 and 8). Means, standard deviations and confidence intervals for
CNS-VS Executive Functioning Domain, Verbal Memory Domain and Visual Memory
Domain standard scores at pre-treatment, post-treatment and one week post-treatment
scores are reported in Table 4.
Three additional independent repeated measures ANOVAs were conducted to
compare mean score differences for executive functioning (WCST), verbal memory
(CVLT-II) and visual memory (RCFT) for pre-treatment, post-treatment and one week
post-treatment time-points. These additional assessments were used as more, wellestablished measures of the aforementioned cognitive domains. The one-way repeated
measures ANOVA of the WCST Total Conceptual Level Responses scores revealed no
statistically significant differences across test administrations, F(2,12) = 0.30, p = .749,
2p = .047, 90% CI [0.000, 0.204]. Thus, in terms of executive functioning as measured
by the WCST, significant improvement was not observed (Figure 9).
The one-way repeated measures ANOVA for CVLT-II long delay free recall
scores revealed statistically significant differences across test administrations, F(2,12) =
9.04, p < .005, 2p = 0.601, 90% CI [0.179, 0.724]. Tukey’s HSD post-hoc analyses
revealed that the post-treatment mean score (10.57 ± 4.16) was not significantly higher
than the pre-treatment mean score (8.57 ± 3.36). However, the one week post-treatment
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mean score (12.71 ± 3.99) was significantly higher than the pre-treatment mean score (p
< .05). While there was an improvement in performance from post-treatment to one
week post-treatment, this was not statistically significant. Thus, in terms of verbal
memory as measured by the CVLT-II, significant improvement was observed, but not
until one week post-treatment (Figure 10).
The one-way repeated measures ANOVA for RCFT delayed recall scores
revealed statistically significant differences across test administrations, F(2,12) = 13.44,
p < .001, 2p = .691, 90% CI [0.306, 0.786]. Tukey’s HSD post-hoc analyses revealed
that the post-treatment mean score (24.29 ± 9.03) was significantly higher than the pretreatment mean score (18.79 ± 6.40). The one week post-treatment mean score (27.93 ±
8.61) was also significantly higher than the pre-treatment mean score (p < .05). While
there was an improvement in performance from post-treatment to one week posttreatment, this was not statistically significant. Thus, in terms of visual memory as
measured by the RCFT, significant improvement was observed at post-treatment and
maintained at one week post-treatment (Figure 11). Means, standard deviations and
confidence intervals for WCST, CVLT-II and RCFT scores at pre-treatment, posttreatment and one week post-treatment scores are reported in Table 4.
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Table 4
Mean Scores, Standard Deviations (SD) and 95% Confidence Intervals [95% CI] at PreTreatment, Post-Treatment and One Week Post-Treatment for CNS-VS Executive
Functioning, Verbal Memory and Visual Memory Domains, and WCST, CVLT-II and
RCFT
Pre-Treatment
Mean (SD)
[95% CI]

Post-Treatment
Mean (SD)
[95% CI]

One Week Post
Mean (SD)
[95% CI]

CNS-VS

71.57 (31.80)
[42.16, 100.98]

91.29 (34.35)
[59.52, 123.05]

98.57 (35.41)
[65.83, 131.32]

WCST

73.71 (12.51)
[62.14, 85.29]

71.42 (10.72)
[61.51, 81.34]

74.29 (15.70)
[61.76, 90.81]

CNS-VS

85.29 (25.36)
[61.84, 108.74]

80.43 (35.90)
[47.23, 113.63]

85.86 (26.82)
[61.05, 110.66]

CVLT-II

8.57 (3.36)
[5.46, 11.67]

10.57 (4.16)
[6.73, 14.42]

12.71 (3.99)
[9.03, 16.40]

CNS-VS

92.57(15.37)
[78.36, 106.79]

93.29 (18.69)
[76.00, 110.57]

91.00 (25.64)
[67.29, 114.71]

RCFT

18.79 (6.40)
[12.87, 24.71]

24.29 (9.03)
[15.94, 32.63]

27.93 (8.61)
[19.96, 35.90]
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Verbal Memory
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Domain Total Score Means
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Figure 6. CNS-VS Executive Functioning Domain 3-Time Point Total Score Means
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Figure 7. CNS-VS Verbal Memory Domain 3-Time Point Total Score Means
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DomainTotal Score Means
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Figure 8. CNS-VS Visual Memory Domain 3-Time Point Total Score Means
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CHAPTER IV
DISCUSSION
More than half of PTSD cases are refractory to the current standard of care (Foa
et al., 2009; Schnyder, 2005). Thus, PTSD remains a chronic illness for many
individuals, despite treatment. In addition to the psychological dysfunction experienced
with PTSD, many patients undergo a debilitating decline in neurocognitive functioning
(Uddo et al., 1993; Polak et al., 2012). Exposure therapy is currently the most efficacious
treatment we have for the treatment of PTSD (Foa et al., 1999; Foa et al., 2005; Foa et al.,
1991; Keane et al., 1989; Resick et al., 2002), with limited research suggesting that the
addition of TMS to exposure therapy may provide increased benefit over exposure
therapy alone (Ousch et al., 2009).
The aim of the present study was to determine if combined TMS and prolonged
imaginal exposure was associated with improvements in PTSD symptoms, concomitant
depression and anxiety symptoms, and neurocognitive functioning. The goal of this aim
was to provide information regarding the safety and utility of TMS combined with
imaginal exposure as an additional modality of treatment for PTSD and declines in
cognitive functioning that often accompany PTSD. A further aim of the study was to
determine if gains associated with the aforementioned treatment were maintained once
treatment had been discontinued. More specifically, patients were assessed using selfreport and clinician administered questionnaires for PTSD, depression, and anxiety
symptoms (PCL-M, TOP-8, BDI-II, HAM-D, and BAI) and neurocognitive tests
measuring executive functioning, verbal memory and visual memory (CNS Vital Signs,
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WCST, CVLT-II, and RCFT) at pre-treatment, post-treatment, and one week posttreatment.
Major Findings
As mentioned above, limited research suggests that the addition of TMS to
exposure therapy may provide increased benefit for reduction of PTSD symptoms (Ousch
et al., 2009). However, in this previous study the imaginal exposure procedure differed
from the standard exposure therapy protocol in that participants could choose to speak
about any past traumatic memory (as opposed to the most distressing memory) or they
could choose to be silent during TMS. Further, in this previous study the SMA, which
has direct afferent connections to the amygdala and thus a likely role in PTSD symptom
maintenance, was not stimulated. Finally, it was unclear in the previous study how many
participants were below the clinical threshold for PTSD post-treatment. Consequently,
findings needed to be replicated with a more standard exposure therapy protocol, with
inclusion of SMA stimulation, and with the inclusion of statistics for percentage of
participants who no longer met criteria for PTSD post-treatment.
The procedure used in the present study was well tolerated by this patient sample,
with the only reported side effect being brief scalp irritation for two patients with very
short hair. No patients dropped out during treatment. This is noteworthy as dropout for
standard PTSD treatments is approximately 20% (Foa et al., 2009; Schnyder, 2005). It is
highly possible that the added TMS began inhibiting fear-maintaining circuits
immediately upon application, thus reducing symptoms quickly enough to prevent
dropout due to avoidance. Avoidance is common in PTSD and likely worsens if
symptom reduction is delayed during treatment, increasing probability of dropout.

65
Further research is warranted to examine factors contributing to treatment tolerance with
PTSD.
As predicted, results for both measures of PTSD symptom severity (PCL-M and
TOP-8) revealed statistically significant reductions in PTSD symptoms from pretreatment to post-treatment, with reductions remaining stable at one week post-treatment.
Effect sizes for both measures were very large, however as sample size is small the
likelihood of sampling error is high. One hundred percent of the sample demonstrated
clinically significant reductions (more than 10-point change) in PTSD symptoms from
pre-treatment to post-treatment on the PCL-M, with 86% (n = 6) of the sample falling
below the 50-point cutoff score for a likely PTSD diagnosis by one week post-treatment.
Thus, it appears as if 86% of patients no longer had PTSD following treatment. With
previous studies using exposure therapy alone indicating that less than 50% of patients
recover from PTSD (Foa et al., 2009; Schnyder, 2005), it is possible that the addition of
TMS to exposure therapy does provide increased benefit for reduction of PTSD
symptoms over exposure alone. Again, comparison across studies is speculative and
inconclusive, particularly as there is no standard of care or control group in the present
study. Additionally, in the present study there was a 51.4% improvement in PTSD
symptoms as measured by the PCL-M, whereas previous studies using only TMS to treat
PTSD found 29.3%-36.9% symptom change with the PCL-M. Moreover, all participants
in the current study had treatment refractory PTSD, demonstrating that the combination
of TMS and exposure therapy may be effective for patients who have not responded to
other PTSD treatments. Were this protocol used as a first line treatment, rather than on a
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treatment refractory sample, the percentage of those who recover from PTSD could be
even greater.
A similar pattern emerged for patients’ concomitant depressive symptoms. As
expected, results for both measures of depressive symptom severity (BDI-II and HAM-D)
revealed statistically significant reductions in depressive symptoms from pre-treatment to
post-treatment, with reductions remaining stable at one week post-treatment. Once again,
effect sizes for both measures were very large, but sampling error in such a small sample
is likely a factor. In terms of clinical significance, 100% of the sample demonstrated
clinically significant reductions (as measured by 1 SD in change from the pre-treatment
measure) in depressive symptoms from pre-treatment to post-treatment on the BDI-II. At
pre-treatment 57% (n = 4) of patients had severe depression as per the BDI-II and the
remaining 43% (n = 3) had moderate depression. By one week post-treatment, 14% (n =
1) of the sample had moderate depression, with 86% (n = 6) of the sample falling below
the 14-point cutoff score for mild depression. Thus, it is possible that 86% of patients no
longer had clinically significant depression following treatment.
Comorbidity studies indicate that depression is one of the most commonly cooccurring disorders with PTSD, with approximately 48% of those with PTSD also having
current or past depression. Those who have had PTSD at some point in their lives are
almost 7 times as likely as people without PTSD to also have depression (Breslau, 2002;
Kessler et al., 2005; Shalev et al., 1998). In the present study comorbid depression was
even more prevalent, with 100% of the sample having co-occurring depression as per the
BDI-II. It may be that comorbid depression contributes to PTSD being chronic and
treatment resistant, thus explaining the difference in comorbidity percentages. PTSD and
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depression may be connected in a number of ways, but the mechanism behind the
connection is not abundantly clear in the literature. Those with depression have been
found to be more likely to have traumatic experiences than people without depression,
which in turn, may increase the likelihood that PTSD develops (Shalev et al., 1998). A
second possibility is that the symptoms of PTSD can be so distressing and debilitating
that they cause depression to develop. While co-morbid disorders can be considered
confounds in treatment studies, given the high co-occurrence of PTSD and depression in
the general population, it could be argued that the improvements of both disorders with
the present treatment renders the combined treatment utilized in the present study more
useful and more ecologically valid. Regardless of the mechanism of action connecting
these disorders, it can be postulated that a treatment associated with remission of both
PTSD and depressive symptoms in 86% of those treated has disrupted the cycle of PTSD
leading to depression, depression leading to PTSD, and so forth.
Regarding anxiety symptoms that are not specific to PTSD, as predicted, results
measured by the BAI revealed a statistically significant reduction from pre-treatment to
post-treatment, with this reduction remaining stable at one week post-treatment. Once
again, the effect size was large, but subject to sampling error due to the small sample
size. In terms of clinical significance, only 43% (n = 3) of the sample demonstrated
significant reductions (as measured by 1 SD in change from the pre-treatment measure)
in anxiety symptoms from pre-treatment to post-treatment on the BAI. This can be
explained, at least in part, by the fact that pre-treatment scores were not as high for
concomitant anxiety symptoms as they were for concomitant depression scores. Forty
three percent of patients reported only mild levels of anxiety at baseline, whereas all
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patients reported moderate to severe levels of depression. Thus, there was less room for
clinical improvement with regard to anxiety. This is expected, given that comorbid
anxiety diagnoses are less common than comorbid depression with PTSD (Kessler et al.,
2005). Two of the three patients with severe anxiety at baseline had clinically significant
improvement, with the third patient being the one who experienced a confounding
adverse event during the study.
The second research question examined whether combined TMS and exposure
therapy was associated with changes in neurocognitive functioning, including executive
functioning, verbal memory and visual memory. Declines in these cognitive domains
have been associated with PTSD (Polak et al., 2012; Uddo et al., 1993). Computerized
neurocognitive tests (CNS-VS) as well as more traditional, well established
neuropsychological tests (WCST, CVLT-II, and RCFT) were used to assess
neurocognitive functioning with mixed results. Specifically, results from the CNS-VS
measures did not appear to coincide with results from the more traditional measures.
In the domain of executive functioning, analyses of the CNS-VS Executive
Functioning Domain demonstrated statistically significant improvement in executive
functioning with a large effect size, but again this must be interpreted with caution due to
the likelihood of sampling error. However, the traditional neuropsychological measure
(WCST) revealed no significant differences from pre-treatment to post-treatment. The
most likely explanation for the difference is that the tests were not measuring the same
construct. Upon closer examination, the CNS-VS Executive Functioning score is
comprised of the results from two computerized tests, the Stroop Test (measuring
selective attention, ability to inhibit, and executive processing speed) and the Shifting
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Attention Test (measuring decision making, set shifting, and reaction time). The WCST
measures primarily pattern recognition and set shifting. And so, the CNS-VS test is a
much broader measure of executive functions, whereas the WCST is more specific. As
such, results may indicate that the present treatment improves executive functioning
broadly, but does not specifically improve set shifting and pattern recognition. A second
explanation could be that patients’ reaction time and processing speed improved, which
in turn improved CNS-VS scores, but not WCST scores as time was not a factor on that
test. A third possible explanation is that the small sample size resulted in a type II error
for the WCST findings. However, this is unlikely as the means and SDs for the WCST
remained approximately equal across all three time points.
With regard to verbal and visual memory, the reverse pattern was found. Namely,
there were no significant improvements on CNS-VS Domain scores (Verbal Memory and
Visual Memory Domains), but there were statistically significant improvements on the
more traditional neuropsychological measures (CVLT-II and RCFT), with large effect
sizes. Again, the most likely explanation is that the CNS-VS tests and the traditional
measures were not measuring the same constructs.
One major difference between the CNS-VS Verbal Memory Domain test and the
CVLT-II is that the stimuli are presented in differing modalities. Specifically, they are
presented visually (on a computer screen) for CNS-VS and verbally (spoken by the test
administrator) for the CVLT-II. Thus, the CNS-VS test requires visual attention and
encoding circuitry, whereas the CVLT-II requires auditory attention and encoding
circuitry. Furthermore, the CNS-VS Verbal Memory Domain test is an assessment of
recognition memory (recognizing the correct words, which are nested among distractors),
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but the measure examined on the CVLT-II is a test of free recall. A third difference is
that words are repeated five times during the encoding phase of the CVLT-II to optimize
learning. However, the CNS-VS presents words only once. So, it may be concluded that
the present treatment is associated with improvements in auditory attention and encoding
of verbal information and delayed free recall of said information, when information is
repeated several times during the encoding phase. However, the treatment was not
associated with improvements in visual attention and recognition memory of verbal
information that is presented only once during the encoding phase. A practical
assessment of these findings may be that patients will likely have improved memory for
conversational information, but not for information they have read.
A final distinction between the CVLT-II and the CNS-VS Verbal Memory test is
that the CVLT-II presents words belonging to four categories (animals, forms of
transportation, vegetables, and furniture) whereas the CNS-VS test presents words that
are not associated with one another in any apparent way. This distinction is important,
because the ability to categorize and associate words as a strategy for remembering
requires intact executive functions. The finding discussed above that the present
treatment is associated with broad improvements in executive functioning may help
explain why improvements were seen on the CVLT-II, with its high degree of executive
involvement, but not on the CNS-VS Verbal Memory test, which does not involve the
same degree of executive functioning. Therefore, another explanation for the differing
results between the CVLT-II and the CNS-VS Verbal Memory test is that the mechanism
of action behind the improvement in verbal memory is actually through the enhancement
in executive functioning, rather than a direct improvement in verbal memory. This
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explanation is supported by previous research indicating that executive functioning, as
measured by Wisconsin Card-Sorting Test, Trail-Making Test-Part B, Controlled Oral
Word Association Test, Animal Naming, and Wechsler Adult Intelligence Scale-Third
Edition Similarities, accounted for substantial variance (24%-31%) in CVLT-II
performance for the Long-Delay Recall index (Hill, Alosco, Bauer & Tremont, 2012).
The literature also indicates correlations between the CVLT-II Long-Delay Recall index
and select subtests of the D-KEFS, a standardized battery of executive functioning (Delis,
Kaplan & Kramer, 2001a; Delis, Kaplan & Kramer, 2001b).
The tests of visual memory are more similar than those for verbal memory, but
there are some important differences. Most notable again is the organizational
component of the RCFT. The RCFT requires the test taker to not only remember visually
presented shapes, but he also must remember how those shapes were organized on the
page. Thus, the test taker must utilize the executive functions of planning and
organization in addition to visual memory. The CNS-VS Visual Memory Domain test
does not have this organizational component. And so again, the mechanism of action
behind the improvement in visual memory may actually be through an enhancement in
executive functioning, rather than a direct improvement in visual memory. Qualitative
findings support the role of executive functioning in RCFT performance (Stern et al.,
1995; Watanabe et al., 2005) but this relationship is not well established as yet through
quantitative research.
A second difference between the tests is that the CNS-VS Visual Memory
Domain test is an assessment of recognition memory (recognizing the correct shapes,
which are nested among distractors), but the measure examined on the RCFT is a test of
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free recall. It may be that the present treatment improves visual free recall but not
recognition memory, or again it may be that the mechanism of action behind the
improvement is through the enhancement in executive functioning, rather than a direct
improvement in visual memory; irrespective of which interpretation is accurate, what is
certain is that the use of a variety of assessments to test what may assumed to be a single
construct is important for an in-depth understanding of possible treatment effects. While
results on measures of psychological symptoms coincided well, results for tests of
neurocognitive functioning were more complex. The use of multiple assessments for
each domain allowed for a more considered and detailed appreciation of cognitive
changes.
A final explanation for the inconsistent findings with regard to neurocognitive
functioning pertains to the shortcomings of statistical analyses with a small sample.
Namely, the nonsignificant results may be attributable to underpowering. Conversely,
the significant results may be due to practice effects or other confounds. These potential
limitations are discussed further below.
Limitations and Design Considerations
A major limitation of the current study is the small sample size. Although a
power analysis determined that a sample size of seven was sufficient for a large effect
size, if the effect sizes were smaller, a larger sample would be required to detect those
effects. Thus, potentially significant results with small or even medium effect sizes may
have been missed due to underpowering. For instance, it may be that with a larger
sample, improvement in other cognitive domains more distal from treatment areas would
be detected. The small sample size is also problematic in that it may not be a good

73
representation of the general population due to likely sampling error in a sample of seven.
Patient recruitment was the primary limiting factor in terms of sample size. This may
have been due to several causes, including the continued lack of awareness and
misunderstandings about TMS. The general population, as well as many healthcare
providers, likely equate any external brain stimulation to ECT, and consequently assume
it has a high likelihood of undesirable side effects. This may have contributed to a
reluctance to refer patients to the study. It was also the case that two potential
participants expressed initial interest, but did not attend any sessions after hearing a
summary of what the treatment entailed. It is impossible to say what prevented them
from attending, but uncertainty about brain stimulation may have been a factor.
Recruitment was also likely limited by the tendency for those with PTSD to avoid
situations that require them to think about their traumatic events.
Generalizability of the findings is further limited as the sample consisted only of
men with combat trauma. While this homogeneity is preferred with such a small sample,
attempts to generalize these findings to women with PTSD or those with non-combat
related PTSD should not be done yet. The literature does show that prolonged exposure
is effective across gender and type of trauma (military and non-military; Foa, et al.,
2009). As such, generalizability of the effects of the current treatment protocol to women
and non-combat trauma seems promising, but replication and more diverse sampling is
needed in the future.
Selection bias is an additional limiting factor as patients self-selected to be a part
of the treatment. As a result, the sample includes only patients who were willing to
undergo a novel and lengthy treatment and set of assessments. They must, as noted
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above, also have been willing to repeatedly recount their past trauma in detail. This
willingness may be an unlikely characteristic of patients with PTSD. A randomized
controlled trial would control to some degree for selection bias as well as the potential
confounds of maturation, order effects such as practice, boredom and fatigue, and the
influence of events outside the experiment, but it would not account completely for the
selection effect of patients willing to participate in a lengthy study.
A double-blind, randomized controlled trial would also help to control for
observer-experimenter expectancy bias, which may have contributed to significant
results. As there was no control group, participants were aware that they were receiving
an innovative and novel treatment, thus they may have expected to improve. This
expectation could have influenced them to report decreased symptoms more readily.
Additionally, there may have been expectancy bias on the part of the treatment
administrators due to the lack of a double-blinded study design. Because this pilot study
suggested clinical improvements and demonstrated the viability of the treatment, further
research incorporating blinded, randomized assignment to either a treatment group or a
control group is warranted. Ideally, further research would also require those
administering treatment to be blinded to the condition by utilizing sham TMS for the
control group. These study design improvements would eliminate observer-experimenter
expectancy biases. In view of the limitations discussed in this paragraph, it may be that
part of the effects found are attributable to a placebo effects rather than the treatment
itself.
Future research should also include more long-term follow-up if possible. While
a post-treatment measure was utilized in the present study, it was taken only one week
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post-treatment taper (4 weeks post daily treatment). Durability of this treatment needs to
be assessed at 3 months, 6 months, etc, particularly as preliminary research on TMS to
treat major depressive disorder indicates a substantial percentage of those who respond to
treatment require maintenance sessions to prevent relapse (Fitzgerald, Grace, Hoy, Bailey
& Daskalakis, 2013; Richieri et al., 2013). Mounting data on the durability of TMS
treatment for refractory depression do suggest that the therapeutic effects of TMS are
durable and that TMS may be successfully used as an intermittent rescue strategy to
preclude impending relapse (Janicak, et al., 2010). If the need for maintenance treatment
is determined, further research on various maintenance protocols should be conducted to
determine frequency and duration of sessions.
The potential for improvement of cognitive functioning due to a psychological
intervention is another limiting factor in interpreting the results of the present study.
Previous research has found that neurocognitive changes do take place independent of
psychological changes following TMS (Bayan, 2014; Vanderhasselt, Raedt, Baeken,
Leyman & D'Haenen , 2009). These previous findings are corroborated by results in the
present study indicating improvement in executive functioning, which is most associated
with a brain region receiving direct TMS stimulation (DLPFC), but no improvement in
non-executive memory, which is most associated with a brain region not directly
stimulated (temporal region). In other words, cognitive gains were only shown for areas
where TMS was applied directly. Additionally, regression analyses were conducted to
examine the relationship between neurocognitive test score changes for measures that
showed statistically significant improvement from pre- to post-treatment (CNS-VS
Executive Functioning Domain, CVLT-II, and RCFT change scores) and change scores
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from pre- to post-treatment for measures of psychological symptom change (PCL-M,
TOP-8, BDI-II, HAM-D and BAI change scores). Results revealed that change scores for
psychological symptoms did not significantly predict neurocognitive change scores in
any of the regression analyses (p < .05). B values for all regression analyses can be seen
in Table 5. These results are noteworthy due to their implications for the potential
treatment of neurocognitive deficits associated with other neuropsychiatric and
neurological illnesses or injuries. This finding replicates previous research demonstrating
the functional impact of TMS’ role in stimulating neuronal activity in focal regions of the
brain implicated with particular cognitive functions (Bayan, 2014). Even so, further
research is warranted to better explain the mechanism of action behind the cognitive
improvements. It is worth stating however, that cognitive improvements are almost
definitely beneficial to the patients regardless of mechanism of action.
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Table 5
B Values Indicating the Relationship between Neurocognitive Test Score Change (CNSVS Executive Functioning Domain, CVLT-II, and RCFT) and Psychological Symptom
Change (PCL-M, TOP-8, BDI-II, HAM-D and BAI)

PCL-M

TOP-8

BDI-II

HAM-D

BAI

CNS-VSEF

.41

-1.35

-3.54

2.56

-.04

CVLT-II

.57

-.34

-.74

.52

-.11

RCFT

.54

-.66

-.75

.79

-.18

* = p < .05; ** = p < .01; ***= p < .00
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A final consideration for future research designs concerns what to include in the
battery. As many measures were utilized in this study, psychological symptoms were
assessed using brief screening measures (PCL-M, TOP-8, BDI-II, HAM-D, BAI) for the
sake of efficiency. However, the gold standard for PTSD assessment is the CAPS.
Future studies focusing solely on PTSD may want to incorporate the CAPS to measure
symptom reductions and not just as an initial interview to determine PTSD diagnosis.
In terms of the neurocognitive battery, interpretation of the results is limited by
the fact that, as noted in the Methods section, the psychometrics of the tests used were not
determined with a sample of men who have PTSD. Rather they are primarily from
samples of normal controls. Thus, generalizing the psychometric properties to the sample
in the present study must be done cautiously. There is no body of literature looking at the
psychometrics of neurocognitive tests in populations with PTSD. When examining the
properties of neurocognitive tests in clinical samples, the focus is often on patients with
overt brain injuries or neurodegenerative processes, and these are not appropriate
comparison groups for the present sample. Further research examining the psychometrics
of commonly used neurocognitive tests in those with PTSD is a much needed addition to
the literature.
Furthermore, the neurocognitive battery chosen for this study could be considered
problematic as it did not prove consistent across cognitive domains. In other words, the
two executive functioning measures did not show equivalent outcomes. The same
inconsistency was found for the measures of verbal and visual memory. However, use of
multiple neurocognitive measures for a single cognitive domain does provide a more
comprehensive view of neurocognitive changes, as well as the limitations in cognitive
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change. Although results may appear contradictory on the surface, a thorough
interpretation of scores and in-depth understanding of what each assessment measures
reveal a more accurate, albeit complex, representation of cognition.
Conclusions
The present study was able to contribute to the current literature regarding TMS
as a safe and beneficial treatment for psychological and neurocognitive symptoms.
Specifically, this study provides support for the use of TMS as a treatment for chronic,
treatment refractory PTSD in men with combat trauma. Results further indicate that the
benefit of low frequency TMS to the RDLPFC and the SMA combined with prolonged
imaginal exposure may exceed the effect of exposure therapy alone and the effect of
TMS alone, as measured by symptom improvement percentages from previous studies..
However, this comparison is merely speculative and requires further research to confirm.
This treatment protocol was also associated with reductions in concomitant symptoms of
depression and anxiety, which are often debilitating comorbidities in those with PTSD.
The clinical improvements associated with the present protocol propound a strong case
for a larger double-blinded RCT examining the statistical significance of the present
treatment protocol as compared to a control. If the results of this pilot study are
replicated in a RCT, the case will be strong for offering this as an FDA approved
treatment for chronic, treatment resistant PTSD. Further, the low side-effect profile
indicates the protocol used in the present study may be appropriate as a first line
treatment for PTSD, if patients do not have any contraindications to TMS.
With regard to neurocognitive function, the present treatment protocol was
associated with improvements in general executive functioning, but not set-shifting
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specifically. Executive functions, often thought of as central command for the brain, play
an integral role in decision making and behavioral guidance. Improvement in these
abilities for those with PTSD, many of whom have a post-diagnosis history of poor
decisions and disordered behavior, will likely lead to improved functioning and better
overall quality of life. Results for tests of verbal and visual memory were inconsistent,
but generally indicate that executive memory is improved both in both verbal and visual
domains. However, results on memory tests that do not have an executive component did
not show improvement. This finding may indicate that cognitive changes are more likely
in domains associated with the areas of the brain receiving direct stimulation, in this case
the prefrontal cortex (associated with executive functions), but not as likely for domains
associated with areas of the brain that must be reached transsynaptically. Many
components of the memory process are associated with the temporal lobes, which were
not directly stimulated in this protocol, and thus may be less likely to show
improvements. It may also be that cognitive changes associated with areas of the brain
treated transynapically occur, but only after a longer period of treatment. This latter
explanation bears some weight given that neuroimaging studies have demonstrated
metabolic and cerebral blood flow alterations in limbic and paralimbic areas of the brain
that cannot be directly stimulated, and thus must be reached transynaptically (Kito, Fugita
& Koga, 2008; Kito, Hasegawa & Koga , 2012; Speer et al., 2000). Neurocognitive
changes were not predicted by measures of psychological change in several regression
analyses, indicating neurocognitive changes likely occur independent of psychological
changes. This is noteworthy due to its implications for the potential treatment of
neurocognitive deficits associated with other neuropsychiatric and neurological illnesses
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or injuries. The results of the present study help to further elucidate how functional
processes may be altered by the changes seen on neuroimaging in previous studies.
However, it must be restated that all conclusions are tentative due to the likelihood of
sampling error and potential confounds.
In summary, this is the first pilot study of its kind to combine TMS to the right
DLPFC and the SMA with a standardized exposure protocol for the treatment of chronic,
treatment-resistant PTSD. The aims were to (1) determine if the treatment was safe and
well tolerated, (2) determine if PTSD and concomitant depression and anxiety symptoms
improved, and (3) determine if executive functioning and memory improved. The
treatment was safe and well tolerated, and improvements were seen across measures with
the exception of non-executive memory, although statistical significance must be viewed
tentatively. Most strikingly, six of the seven participants no longer met criteria for PTSD
by the end of the study. A PTSD treatment that improves psychological and
neurocognitive symptoms with minimal side effects has immense utility in improving
functionality and quality of life for combat veterans, and possibly for other populations
with PTSD. Results for this pilot study are promising, but larger studies utilizing a RCT
model are needed to confirm and expand upon these very preliminary findings. If
findings are well confirmed, steps for FDA approval of the procedure used in the present
study would be warranted.
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APPENDIX
Table 6
Correlations between Potential Covariates and CNS-VS Neurocognitive Domain Scores
(Executive Functioning, Verbal Memory, Visual Memory) at 3 Time Points (PreTreatment, Post-Treatment, 1 Week Post-Treatment)

Variables

Executive Function

Verbal Memory

Visual Memory

Pre

Post

1WP

Pre

Post

1WP

Pre

Post

1WP

Baseline PCL-M

-.14

.39

.29

.33

.59

.20

.20

.05

.33

Baseline TOP-8

.00

.26

.16

.21

.32

.00

-.16

.00

.41

Baseline BDI-II

-.29

.25

.15

.20

.55

.25

.25

.10

.20

Baseline HAM-D

-.20

.15

.05

.39

.35

.15

-.05

.29

.49

Baseline BAI

-.33

.20

.10

.14

.39

.20

.20

.05

.14

Age

-.59

-.15

-.05

-.39

-.25

.05

.15

-.29

-.49

Education Level

.44

.33

.37

.20

.16

.44

.42

.30

.07

Race

.46

.32

.30

.17

.18

-.04

.10

-.07

.05

* = p < .05; ** = p < .01; ***= p < .00
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Table 7
Correlations between Potential Covariates and WCST, CVLT-II, and RCFT scores at 3
Time Points (Pre-Treatment, Post-Treatment, 1 Week Post-Treatment)

Variables

WCST
Pre

CVLT-II

RCFT

Post

1WP

Pre

Post

1WP

Pre

Post

1WP

Baseline PCL-M

-.29

-.15

-.43

.49

.62

.59

-.33

.10

.24

Baseline TOP-8

-.37

-.32

-.41

.16

.51

.32

.10

.26

.10

Baseline BDI-II

-.45

-.10

-.39

.35

.49

.55

-.39

-.05

.10

Baseline HAM-D

-.20

-.26

-.29

.15

.20

-.15

.00

.05

.25

Baseline BAI

-.29

-.05

-.24

.49

.43

.59

-.52

-.10

.05

Age

-.20

.46

.49

-.15

-.20

-.05

-.39

-.65*

-.49

Education Level

.81*

.26

.20

-.07

-.12

.20

.42

.36

.45

Race

-.13

-.10

-.28

.60

.41

.15

-.27

.09

.10

* = p < .05; ** = p < .01; ***= p < .00
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